The Weekly Term Sheet (2026-W14)
W14 (March 29–April 5, 2026) opened with the formal announcement of the week's headline deal: Eli Lilly's $2.75 billion global R&D collaboration with Insilico Medicine, upgrading the FT-previewed $2 billion GLP-1 license reported in W13 into a broader, multi-target AI drug discovery partnership.
On Monday, Royalty Pharma committed $500 million to co-fund Johnson & Johnson's dual-pathway autoimmune antibody JNJ-4804, a deal that simultaneously validates the R&D co-funding model and positions RPRX at the center of the next-generation immunology royalty landscape. Aurinia Pharmaceuticals announced a ~$50 million acquisition of Kezar Life Sciences in a CVR-structured tender offer orchestrated by Kevin Tang, adding a first-in-class immunoproteasome inhibitor to the lupus nephritis company's pipeline.
On Tuesday, Galapagos and Gilead signed their binding Framework Agreement on the Ouro Medicines collaboration, finalizing the 20-23% royalty structure and $837.5 million cost-sharing arrangement previewed in W13.
On Tuesday morning, W14's two largest transactions broke simultaneously: Biogen announced a $5.6 billion acquisition of Apellis Pharmaceuticals ($41/share cash plus a CVR paying up to $4/share tied to SYFOVRE global sales thresholds), adding two commercialized complement therapies generating $689 million in combined 2025 revenue, while Eli Lilly announced a $6.3 billion acquisition of Centessa Pharmaceuticals ($38/share cash plus up to $9/share in CVRs), adding a potential best-in-class orexin receptor 2 agonist pipeline for sleep-wake disorders. The two deals bring Tuesday's announced M&A value alone to nearly $13 billion. Also on Tuesday, Merck and Infinimmune announced an $838 million antibody discovery collaboration deploying the Anthrobody platform and GLIMPSE language model across multiple immunology targets.
United Therapeutics delivered one of 2026's most important clinical catalysts with a +130 mL FVC improvement in the Phase 3 TETON-1 study of inhaled treprostinil in IPF, sending shares up 16% and opening a potential $5-10 billion market.
Three FDA approvals landed across the week: Biogen's Spinraza High Dose regimen for SMA (March 30), Teva's PONLIMSI (denosumab biosimilar, March 30), and — in the week's single most commercially consequential regulatory action — Eli Lilly's Foundayo (orforglipron) (April 1), the first oral small-molecule GLP-1 receptor agonist approved for weight management. Vertex also received expanded labels for both ALYFTREK and TRIKAFTA on April 1, extending CF modulator coverage to approximately 95% of the U.S. CF population.
Viridian Therapeutics reported positive Phase 3 REVEAL-1 results for elegrobart in thyroid eye disease, but shares plunged 32-40% on below-expectation proptosis response rates — a result immediately followed on April 2 by Immunovant's announcement that both Phase 3 GO studies of batoclimab in TED also missed their primary endpoint, effectively resetting the competitive landscape in that indication.
Also on April 2, Lipocine reported that LPCN 1154 (oral brexanolone) failed its Phase 3 primary endpoint in postpartum depression, though a favorable safety profile and post hoc subset signals leave a narrow path forward. Priovant Therapeutics (Roivant) announced the initiation of a Phase 2b/3 study of brepocitinib in lichen planopilaris, adding a fourth late-stage indication to its JAK1/TYK2 franchise ahead of its anticipated dermatomyositis launch in September 2026.
The ACC.26 annual meeting in New Orleans produced several late-breaking presentations with direct commercial relevance, including Amgen's VESALIUS-CV primary prevention data for Repatha, BMS's pediatric SCOUT-HCM data for Camzyos, Merck's CADENCE proof-of-concept for Winrevair in CpcPH-HFpEF, and Ionis's negative ESSENCE-CTA plaque substudy for olezarsen. Two ACC.26 readouts stood out: Merck's CORALreef AddOn Phase 3 showing 64.6% LDL-C reduction for oral PCSK9 inhibitor enlicitide decanoate, and BridgeBio's ATTRibute-CM open-label extension demonstrating 45% all-cause mortality reduction for acoramidis at Month 54.
The AAD 2026 annual meeting running concurrently through March 31 delivered pivotal dermatology readouts: Alumis's ONWARD1/ONWARD2 Phase 3 (envudeucitinib, TYK2 inhibitor, PASI 90 ~57-60% in psoriasis), Takeda's zasocitinib Phase 3 (competing TYK2 inhibitor, PASI 90 ~57-61%), Incyte's STOP-HS1/2 54-week data for povorcitinib in hidradenitis suppurativa, and Biogen's AMETHYST Part A Phase 2 positive results for litifilimab in cutaneous lupus erythematosus.
Also on Tuesday, Scynexis acquired PXL770 from Poxel for up to $196 million in upfront and milestones, adding a first-in-class AMPK activator for polycystic kidney disease alongside a concurrent $40 million PIPE to fund development.
On the financing side, Blackstone closed BXLS VI at its $6.3 billion hard cap, the largest private fund ever dedicated to life sciences and nearly 40% larger than its predecessor. Kailera Therapeutics filed its S-1 for a Nasdaq IPO, backed by over $1 billion in private capital and a Phase 3 oral obesity program.
Ambrosia Biosciences raised an oversubscribed $100 million Series B for its next-generation oral small-molecule GLP-1 program. Syneron Bio closed a $150 million Series B backed by AstraZeneca, ADIA, and Temasek for its macrocyclic peptide discovery platform.
Cyclerion Therapeutics and Korsana Biosciences announced an all-stock reverse merger with a concurrent ~$380 million private financing led by Fairmount and Venrock, combining one of the week's largest private capital raises with a Nasdaq listing vehicle.
Fortress Biotech's subsidiary Cyprium Therapeutics sold a Rare Pediatric Disease Priority Review Voucher for $205 million, generated from the ZYCUBO approval for Menkes disease, while retaining tiered royalties and milestones through commercial partner Sentynl Therapeutics. Two additional PRVs were formally issued during the week — to Ascendis Pharma (YUVIWEL, achondroplasia) and Rocket Pharmaceuticals (KRESLADI, LAD-I) — adding new tradeable vouchers to the PRV market.
Additional financings included Centivax ($37 million, Sam Altman's Structure Fund), Scynexis ($40 million PIPE), Aprea Therapeutics ($30 million), and Connect Biopharma ($20.2 million).
The distress ledger was the heaviest since W10: IO Biotech filed for Chapter 7 liquidation (March 31) following its pivotal melanoma trial failure and FDA rejection, Iterum Therapeutics had Nasdaq trading suspended April 1 after appointing joint provisional liquidators in Ireland, and Novo Nordisk announced approximately 400 layoffs at its Bloomington, Indiana manufacturing site — roughly 22% of the workforce at the former Catalent facility acquired in 2025.
Section 232 Pharmaceutical Tariffs (April 2)
President Trump signed a Section 232 proclamation on April 2 imposing 100% ad valorem tariffs on imported patented pharmaceuticals and active pharmaceutical ingredients — the most consequential pharmaceutical trade policy action in a generation. After the Supreme Court's 6-3 ruling on February 20 struck down IEEPA-based emergency tariffs, the administration pivoted to Section 232 of the Trade Expansion Act as its legal mechanism, a provision previously used for steel and aluminum but never for pharmaceuticals.
The proclamation creates a tiered rate structure tied to bilateral pricing and onshoring commitments:
- Companies that sign MFN pricing agreements with HHS and domestic manufacturing agreements with Commerce qualify for a 0% rate through January 2029.
- Country-specific bilateral rates are set at 15% for the EU, Japan, Korea, and Switzerland; the UK rate is 10%, reducible to 0% pursuant to the US-UK pharmaceutical pricing agreement reached in principle on December 1, 2025.
- Companies with Commerce-approved onshoring plans qualify for a 20% reduced rate escalating to 100% on April 2, 2030 (a single cliff, not graduated annual increases).
- Generic drugs and biosimilars are fully exempt, subject to a one-year interagency review.
- Additional product-category exemptions at 0% include orphan drugs (where all approved indications carry orphan designation), cell and gene therapies, antibody-drug conjugates, nuclear medicines, plasma-derived therapies, and fertility treatments — all from trade-deal jurisdictions.
Effective dates are July 31, 2026 for 17 large companies listed in Annex III and September 29, 2026 for all others. The administration cited approximately $400 billion in pharmaceutical manufacturing commitments it claims have already been induced.
Annex II: 13 Companies with Pre-Signed Zero-Tariff Agreements
The proclamation identifies 13 companies that completed both MFN pricing and onshoring agreements with the Secretaries of HHS and Commerce before the April 2 proclamation, qualifying for 0% tariff through January 20, 2029:
AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, EMD Serono (Merck KGaA), Genentech (Roche), Gilead Sciences, Merck & Co., Novartis, Novo Nordisk, and Sanofi.
Four Annex III large companies — GlaxoSmithKline/ViiV Healthcare, Johnson & Johnson, Pfizer, and Regeneron — are notably absent from Annex II, meaning they face the July 31, 2026 effective date at 15% (bilateral) or higher rates unless agreements are finalized.
For royalty investors, assets manufactured by non-Annex II companies in non-trade-deal jurisdictions face the greatest near-term tariff cost exposure.
STAT News and Fierce Pharma reported extensively on April 3 on coordinated industry pushback: smaller biotech investors sent a public letter to the administration arguing the tariffs would suppress U.S. early-stage R&D investment and raise patient costs without meaningfully reshoring the complex biologics manufacturing that represents the majority of pharma import value.
Large-cap pharma companies with significant U.S. manufacturing footprints (Lilly, Pfizer, Merck, AbbVie) are better positioned to negotiate bilateral MFN deals; smaller biotechs dependent on contract manufacturers in Ireland, Switzerland, and Germany face the greatest near-term cost exposure.
Royalty financing implications: Section 232 tariffs create structural uncertainty for royalty deal underwriting in several dimensions:
- Any royalty stream denominated in U.S. net sales is partially insulated — tariffs are a cost-of-goods issue, not a net sales reduction — but they compress net margins of licensees and thus their capacity to service royalty obligations.
- Geographic reconfiguration of manufacturing to onshore production may alter the jurisdictional basis of royalty payments and trigger recharacterization questions under existing license agreements.
- Royalty investors evaluating deals on assets manufactured primarily outside the U.S. will need to model tariff cost pass-through scenarios into their royalty coverage ratio analysis.
Japan-specific royalty context (Athyrium/Esperion): The 15% bilateral rate for Japan is directly relevant to the Athyrium/Esperion Japan royalty deal covered in this issue. The Athyrium royalty is calculated on Otsuka's Japan domestic net sales — not on U.S. imports — meaning the tariff does not directly reduce the royalty base.
However, if bempedoic acid API or finished product relies on non-Japanese manufacturing inputs subject to import tariffs in Japan (a bilateral dynamic that may emerge under reciprocal trade responses), Otsuka's effective cost of goods could rise, reducing marketing investment headroom. This is a second-order risk that royalty investors in Japan-denominated streams should model under tariff escalation scenarios.
Biogen / Apellis Pharmaceuticals: $5.6 Billion Complement Therapeutics Acquisition with CVR (March 31)
On March 31, Biogen (NASDAQ: BIIB) and Apellis Pharmaceuticals (NASDAQ: APLS) announced a definitive agreement under which Biogen will acquire all outstanding shares of Apellis for $41.00 per share in cash, representing an upfront equity value of approximately $5.6 billion. Apellis shareholders will also receive a non-transferable CVR for each share held.
Deal Structure
| Term | Detail |
|---|---|
| Acquirer | Biogen Inc. (NASDAQ: BIIB) |
| Target | Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) |
| Cash consideration | $41.00 per share |
| Upfront equity value | ~$5.6 billion |
| Premium (90-day VWAP) | 86% |
| Premium (52-week high) | 35% |
| CVR | Non-transferable; $2/share if SYFOVRE achieves $1.5 billion in annual global net sales in any calendar year 2027-2030; additional $2/share if SYFOVRE achieves $2 billion in any of those years; if neither threshold met but SYFOVRE hits $2 billion in 2031, a single $4/share payment |
| Total potential consideration | Up to $45.00 per share ($41 + $4 CVR) |
| Structure | Tender offer followed by second-step merger |
| Expected close | Q2 2026 |
| 2025 combined product revenue | $689 million (EMPAVELI + SYFOVRE) |
| Revenue growth outlook | Mid-to-high teens CAGR at least through 2028 |
| EPS impact | Increasingly accretive to non-GAAP diluted EPS starting 2027 |
Advisors
| Role | Firm |
|---|---|
| Biogen financial advisor | Lazard (sole) |
| Biogen legal counsel | Cravath, Swaine & Moore LLP and Arnold & Porter |
| Apellis financial advisor | Evercore (sole) |
| Apellis legal counsel | Wachtell, Lipton, Rosen & Katz and WilmerHale |
Assets Acquired
SYFOVRE (pegcetacoplan injection) is the first-ever approved therapy for geographic atrophy (GA) secondary to age-related macular degeneration, targeting complement component C3. In Phase 3 OAKS and DERBY studies, SYFOVRE reduced GA lesion growth by up to 36% at 24 months with monthly treatment. Five-year GALE extension data showed SYFOVRE delayed GA progression by approximately 1.5 years in nonsubfoveal GA patients. A prefilled syringe application is planned for H1 2026.
EMPAVELI (pegcetacoplan) is a targeted C3 therapy approved in the U.S. for three indications: C3 glomerulopathy (C3G), primary IC-MPGN (in patients 12+ years), and PNH. In the Phase 3 VALIANT study, EMPAVELI demonstrated a 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits versus placebo. Sobi retains commercial rights to EMPAVELI (as Aspaveli) outside the U.S.
Strategic Context
The acquisition extends Biogen's ongoing transformation under CEO Chris Viehbacher, adding two differentiated complement-targeting medicines with combined $689 million in 2025 revenue growing at mid-to-high teens rates. The nephrology angle is particularly strategic: Apellis's U.S. commercial infrastructure and C3G/IC-MPGN expertise will accelerate Biogen's launch readiness for felzartamab, currently in Phase 3 for three kidney diseases with the first readout expected H1 2027. Biogen expects to finance the acquisition with a combination of cash and borrowings and believes it can fully de-lever by end of 2027.
The CVR structure is notable: the two-tiered design ($2 at $1.5 billion sales, additional $2 at $2 billion) creates a transparent pricing mechanism for SYFOVRE's commercial trajectory, with a backstop provision allowing a single $4 payment if the $2 billion threshold is met only in 2031. The non-transferable structure follows the dominant 2025-2026 CVR trend, preventing secondary market trading and price discovery.
Upstream IP and Royalty Stack
Pegcetacoplan (the active ingredient in both SYFOVRE and EMPAVELI) is a C3-targeted cyclic peptide conjugated to polyethylene glycol (PEG). The compound was developed internally by Apellis, co-founded by Cedric Francois, M.D., Ph.D. and Pascal Deschatelets, Ph.D. in 2009 to advance complement science derived from foundational research at the University of Pennsylvania. Biogen inherits the full royalty stack upon closing.
Layer 1 — Potentia Pharmaceuticals: Apellis licensed pegcetacoplan from Potentia Pharmaceuticals in 2011. Potentia was a spin-out from University of Colorado and University of Utah complement biology work. Apellis's 10-K discloses a royalty obligation to Potentia on net sales with the specific rate redacted; based on comparables for early-stage academic spin-out licenses in the complement space at that vintage, the rate is estimated at mid-single digits (~3–6%). Potentia is no longer an independent operating company, meaning these royalty flows accrue to its assignees or acquirers.
Layer 2 — PEGylation technology (NOF Corporation): Apellis's license exhibit list references a PEGylation technology license from NOF Corporation (Japan), consistent with NOF's SUNBRIGHT® PEG reagent platform. NOF typically charges per-gram manufacturing fees rather than sales royalties, making this a COGS encumbrance rather than a top-line royalty drag.
Layer 3 — University of Colorado (complement pathway IP): The core complement C3 cleavage biology traces to academic work at the University of Colorado (John Holers laboratory). A sponsored research and license agreement between Apellis and the University of Colorado was disclosed in Apellis's 2019 S-1, with royalty rates redacted. Estimated at sub-1% consistent with early-stage academic complement licenses of that vintage.
Downstream — Sobi (Aspaveli, ex-U.S.): Sobi (Swedish Orphan Biovitrum) holds exclusive commercial rights to pegcetacoplan (marketed as Aspaveli) outside the United States for PNH and potentially other indications. Sobi pays tiered double-digit royalties (~10–20% tiered) to Apellis/Biogen on Aspaveli ex-U.S. net sales, and made an upfront payment of $250M plus up to $1.25B in milestones. This creates a meaningful royalty inflow that partially offsets U.S. royalty outflows.
| Layer | Direction | Recipient | Est. Rate |
|---|---|---|---|
| Potentia Pharmaceuticals | Outflow | Potentia (assignees) | ~3–6% |
| University of Colorado | Outflow | UC academic license | ~<1% |
| NOF Corporation (PEGylation) | Outflow (COGS) | NOF | Per-gram fee, not % of sales |
| Sobi (ex-U.S. Aspaveli) | Inflow | Biogen | ~10–20% tiered |
| Net U.S. royalty outflow | ~3.5–7% |
Legal advisors: Cravath Swaine & Moore (Biogen); WilmerHale (Apellis).
Royalty financing relevance: very high. The combination of $689 million in existing revenue growing at mid-to-high teens rates, two approved products across four indications, Biogen's investment-grade balance sheet, and a net royalty outflow of only ~3.5–7% creates an exceptionally attractive synthetic royalty financing profile. The Sobi inflow further improves the net economics from a royalty investor's perspective.
Eli Lilly / Centessa Pharmaceuticals: $6.3 Billion Orexin Acquisition with $1.5 Billion CVR (March 31)
On March 31, Eli Lilly (NYSE: LLY) and Centessa Pharmaceuticals (NASDAQ: CNTA) announced a definitive agreement for Lilly to acquire all of Centessa's issued and to-be-issued share capital for $38.00 per share in cash plus one non-transferable contingent value right (CVR) entitling holders to up to $9.00 per share in additional payments. The upfront cash represents an aggregate equity value of approximately $6.3 billion, with the CVR representing an additional potential $1.5 billion.
Deal Structure
| Term | Detail |
|---|---|
| Acquirer | Eli Lilly and Company (NYSE: LLY) |
| Target | Centessa Pharmaceuticals plc (NASDAQ: CNTA) |
| Cash consideration | $38.00 per share |
| Upfront equity value | ~$6.3 billion |
| Premium (30-day VWAP) | 40.5% |
| CVR (milestone i) | $2.00/share upon FDA approval of cleminorexton or ORX142 for narcolepsy type 2 within 5 years of closing |
| CVR (milestone ii) | $5.00/share upon FDA approval of cleminorexton or ORX142 for idiopathic hypersomnia within 5 years of closing |
| CVR (milestone iii) | $2.00/share upon first FDA approval of cleminorexton or ORX142 for any indication prior to January 1, 2030 |
| Total potential per share | Up to $47.00 ($38 + $9 CVR) |
| Total potential equity value | Up to ~$7.8 billion |
| Structure | Scheme of arrangement under English and Welsh law |
| Expected close | Q3 2026 |
| Shareholder support | Medicxi Ventures, Index Ventures, and General Atlantic affiliates (~24.1% of outstanding shares) signed voting agreements |
Advisors
| Role | Firm |
|---|---|
| Lilly financial advisor | Morgan Stanley (exclusive) |
| Lilly legal counsel | Kirkland & Ellis LLP |
| Centessa financial advisors | Centerview Partners and Jefferies |
| Centessa legal counsel | Goodwin Procter LLP |
Pipeline Acquired: Orexin Receptor 2 Agonists
Centessa's pipeline centers on orexin receptor 2 (OX2R) agonists designed to restore wakefulness by directly activating the neurobiological system governing the sleep-wake cycle. The orexin system is the same pathway targeted by sleep-promoting orexin receptor antagonists (suvorexant/Belsomra, lemborexant/Dayvigo), but Centessa's agonists work in the opposite direction, promoting wakefulness rather than sleep.
Cleminorexton (formerly ORX750) is Centessa's lead candidate, a selective OX2R agonist that has demonstrated a potential best-in-class profile in Phase 2a studies across three indications: narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH). Narcolepsy affects approximately 200,000 Americans, with current treatments (Xyrem/Xywav, pitolisant/Wakix, solriamfetol/Sunosi) addressing symptoms rather than the underlying orexin deficiency. Idiopathic hypersomnia affects a similar number but has only one FDA-approved therapy (Xywav, approved 2021).
The pipeline also includes ORX142 and additional preclinical OX2R agonists targeting broader neurological, neurodegenerative, and neuropsychiatric conditions, reflecting the growing recognition that orexin signaling influences cognition, attention, and mood regulation beyond sleep-wake control.
Strategic Context: Lilly's Neuroscience Expansion
This is Lilly's second major deal announced in the W14 window (after the $2.75 billion Insilico AI collaboration on March 29) and its second-largest acquisition of 2026 after the $6.7 billion Terns Pharmaceuticals CML deal announced in W13. The acquisition extends Lilly's neuroscience portfolio, led by Carole Ho (EVP, Lilly Neuroscience), into sleep medicine, a therapeutic area with significant unmet need and limited competition.
The CVR structure is notable for its indication-specific design: the largest single tranche ($5.00/share) is tied to idiopathic hypersomnia approval, reflecting the higher commercial value of this larger, underserved market compared to narcolepsy. The $2.00/share "any indication" milestone (milestone iii) provides a floor payment if the program achieves any FDA approval before 2030, even if the specific NT2 and IH indications are not yet approved.
The scheme of arrangement structure (rather than a tender offer) reflects Centessa's English incorporation and requires shareholder vote plus High Court sanction.
Upstream IP and Royalty Stack
Centessa's orexin program originated from the company's founding in 2020, when Medicxi assembled Centessa from multiple subsidiary companies ("asset-centric" model). The OX2R agonist program was initially housed in Orexia Ltd., one of Centessa's founding subsidiaries, led by Mario Alberto Accardi, Ph.D.
UT Southwestern / Yanagisawa IP: The foundational orexin discovery (1998) by Masashi Yanagisawa's laboratory at UT Southwestern was patented and licensed broadly in the early 2000s — principally to GSK and Merck for their orexin receptor antagonist programs (Belsomra/suvorexant, lemborexant). Critically, these foundational patents cover orexin peptides and antagonist scaffolds, not small-molecule agonists. Centessa's OX2R agonist chemotypes are mechanistically and structurally distinct from the antagonist IP covered by the Yanagisawa/UT Southwestern patents. Centessa's 20-F discloses no license from UT Southwestern, Scripps, or other academic institutions on cleminorexton or ORX142. The OX2R agonist IP appears entirely proprietary to Centessa/Medicxi. Conclusion: clean royalty stack. The CVR payments ($2 NT2, $5 IH, $2 any-indication) flow to Centessa shareholders without upstream royalty deduction.
Royalty financing relevance: high (post-approval). The clean IP stack is a significant positive for royalty investors — no academic royalty drag on the CVR cashflows. The combination of narcolepsy/IH orphan-adjacent populations, mechanistic differentiation (agonist vs. antagonist), Lilly's commercial scale, and the CVR's indication-specific milestones creates a clear royalty valuation roadmap. Pre-approval, the Phase 2a stage limits immediate royalty financing, but the CVR structure itself functions as a synthetic milestone instrument that royalty investors can model against.
Shionogi: $2.5 Billion Radicava (Edaravone) Global Rights Acquisition Closes (April 1)
Shionogi & Co. completed the acquisition of all global rights to Radicava (edaravone) for ALS from Tanabe Pharma Corporation (a subsidiary of Mitsubishi Tanabe Pharma) on April 1, following the deal's announcement on December 22, 2025. The transaction involves a $2.5 billion lump-sum payment plus potential future royalties payable to Tanabe Pharma on net sales.
| Term | Detail |
|---|---|
| Acquirer | Shionogi & Co., Ltd. (TSE: 4507) |
| Seller | Tanabe Pharma Corporation (subsidiary of Mitsubishi Tanabe Pharma) |
| Asset | Global rights to Radicava / Radicava ORS (edaravone) for ALS |
| Consideration | $2.5 billion lump sum + ongoing royalties to Tanabe Pharma |
| Close date | April 1, 2026 |
| New subsidiary | RADIANCE NEWCO LLC, Florham Park, NJ (~143 employees) |
| 2025 global revenues | Approximately $700 million |
| U.S. patients treated | Over 22,000 since U.S. approval |
Radicava is the only approved IV and oral (Radicava ORS) edaravone formulation for ALS in the U.S., with FDA approval in 2017 (IV) and 2022 (oral suspension). It generated approximately $700 million in annual global sales, concentrated in the U.S. and Japan. The $2.5 billion acquisition price implies a roughly 3.6x revenue multiple, consistent with single-indication rare disease asset transactions where revenue durability and patent protection are the primary valuation drivers. Edaravone's U.S. composition-of-matter patent protection extends to 2035.
The deal positions Shionogi — historically a Japan-focused antibiotics and HIV company — as a meaningful U.S. neurology commercial operator and creates a platform for further CNS acquisitions. The creation of RADIANCE NEWCO LLC as a standalone U.S. entity with 143 employees from Tanabe Pharma's former commercial operations preserves the existing U.S. salesforce and payer relationships.
Royalty financing relevance: high. Radicava's $700 million revenue base, orphan drug economics, and 2035 patent runway make it a natural candidate for royalty monetization — either by Shionogi (to partially recoup the $2.5 billion outlay) or by Tanabe Pharma against its ongoing royalty stream. The structure echoes prior ALS royalty transactions where predictable chronic-disease revenue and high drug pricing create attractive royalty economics.
Aurinia Pharmaceuticals / Kezar Life Sciences: ~$50 Million Acquisition with CVR
On March 30, Aurinia Pharmaceuticals (NASDAQ: AUPH) announced a definitive agreement to acquire Kezar Life Sciences (NASDAQ: KZR) in an all-cash tender offer at $6.955 per share plus one non-transferable contingent value right (CVR).
Deal Structure
| Term | Detail |
|---|---|
| Acquirer | Aurinia Pharmaceuticals (NASDAQ: AUPH) |
| Target | Kezar Life Sciences (NASDAQ: KZR) |
| Cash consideration | $6.955 per share |
| CVR | One non-transferable CVR per share, tied to three streams |
| Approximate equity value | ~$50 million (based on ~7.32 million shares outstanding) |
| Structure | Tender offer followed by back-end merger |
| Tender offer launch | By April 13, 2026 |
| Minimum condition | Majority of outstanding shares tendered; Kezar net cash exceeds $50 million |
| Expected close | Q2 2026 |
CVR Economics
The CVR entitles holders to payments tied to three distinct streams: (i) clinical development or disposition proceeds from zetomipzomib, Kezar's first-in-class immunoproteasome inhibitor; (ii) proceeds from Kezar's existing collaboration with Everest Medicines and the sale of its Sec61 program to Enodia Therapeutics; and (iii) 100% of Kezar's closing net cash in excess of $50 million, net of CVR-related expenses.
Tang Capital and Strategic Backstory
The deal carries significant corporate governance context. Kevin Tang, CEO of Tang Capital Management, was named Aurinia CEO the prior week. Tang had previously attempted to acquire Kezar through his vehicle Concentra Biosciences in 2024, but was rebuffed by Kezar's board. Tang Capital Partners holds approximately 9.0% of Kezar's outstanding common stock and has signed a tender and support agreement for the current deal.
The lead asset, zetomipzomib, demonstrated clinically meaningful steroid-sparing remissions in the Phase 2 PORTOLA study in autoimmune hepatitis, with favorable FDA feedback from a recent Type C meeting designed to accelerate the development path.
Advisors
| Role | Firm |
|---|---|
| Kezar financial advisor | TD Cowen |
| Kezar legal counsel | Cooley LLP (Bill Roegge, Rita Sobral, Laura Berezin, Jaime Chase, Parth Bhatt) |
| Aurinia financial advisor | Not disclosed |
| Aurinia legal counsel | Not disclosed |
Royalty financing relevance: low-to-moderate. Zetomipzomib is Phase 2 stage in a niche autoimmune indication. If it advances into Phase 3, the clean IP profile and orphan disease economics could make it attractive for synthetic royalty financing, but this is premature today.
Upstream IP and Royalty Stack: Amgen's Shadow
Zetomipzomib was not developed internally at Kezar. It was licensed in June 2015 from Onyx Therapeutics, a wholly owned Amgen subsidiary, under an exclusive worldwide license. The IP chain traces from Proteolix (founded ~2005) to Onyx (acquired Proteolix in 2009 for ~$900 million) to Amgen (acquired Onyx in 2013 for $10.4 billion) to Kezar (out-licensed 2015). Amgen/Onyx also received a minority equity stake in Kezar at founding, estimated at approximately 1–3% of current outstanding shares following dilution from subsequent financing rounds.
Royalty rate to Amgen: Kezar's 10-K discloses tiered royalties to Amgen/Onyx in the mid-single digits, estimated at 4–6% at lower sales tiers, escalating to 7–8% at higher thresholds. The royalty term extends per-country until the latest of patent expiration, loss of regulatory exclusivity, or the 10th anniversary of first commercial sale, with patent coverage through at least 2034. Aurinia inherits up to $167.5 million in remaining milestones ($5 million already paid in 2023) in addition to the ongoing royalty.
Sublicense obligation: When Kezar sub-licensed to Everest Medicines (Greater China), it owed Amgen/Onyx a low-to-mid teens percentage of sublicense revenue received — meaning a portion of the $7M Everest upfront and up to $125.5M in Everest milestones flow back to Amgen before reaching Kezar (and ultimately CVR holders).
Everest Medicines inflow (CVR pass-through): Everest pays Kezar tiered royalties on Greater China net sales in the high single digits to low double digits (~8–12% tiered), per Kezar's 10-K disclosure. These inflows pass through the CVR to Aurinia shareholders post-close.
| Layer | Direction | Party | Est. Rate |
|---|---|---|---|
| Amgen/Onyx license | Outflow (ex-China) | Amgen | ~4–8% tiered |
| Amgen sublicense share | Outflow (Greater China sublicense income) | Amgen | ~low-to-mid teens % of sublicense revenue |
| Everest Medicines (Greater China) | Inflow → CVR | Kezar → CVR holders | ~8–12% tiered |
No separate academic institution IP was identified for the immunoproteasome program. Enodia Therapeutics purchased the Sec61 program in March 2026 for $1 million upfront plus up to $127 million in milestones, also flowing through the CVR.
Scynexis / Poxel: $196 Million ADPKD Asset Acquisition (March 31)
On March 31, Scynexis (NASDAQ: SCYX) announced the completion of a definitive asset acquisition agreement with Poxel SA (Euronext: POXEL) to acquire PXL770 (now SCY-770), a first-in-class direct activator of adenosine monophosphate-activated protein kinase (AMPK) for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
Deal Structure
| Term | Detail |
|---|---|
| Acquirer | Scynexis, Inc. (NASDAQ: SCYX) |
| Seller | Poxel SA (Euronext: POXEL) |
| Asset | PXL770 (renamed SCY-770), clinical-stage direct AMPK activator |
| Indication | Autosomal dominant polycystic kidney disease (ADPKD) |
| Upfront payment | $8 million |
| Development milestones | Up to $8 million (Phase 2 initiation: $2M; Phase 3 initiation or first US MAA approval: $6M) |
| Commercial milestones | Up to $180 million (triggered at $250M, $500M, $1B, and $1.5B annual net sales thresholds) |
| Total potential consideration | Up to $196 million |
| FDA designation | Orphan Drug Designation for ADPKD |
| Patent protection | Through at least 2041 (without extension) |
| Next milestone | Phase 2 proof-of-concept study initiation Q4 2026; first efficacy readout H2 2027 |
Commercial Milestone Detail
| Triggering Event | Payment |
|---|---|
| Phase 2 clinical trial initiation | $2 million |
| Phase 3 initiation or first US marketing approval (whichever first) | $6 million |
| First US commercial sale | $25 million |
| Calendar year net sales >= $250 million | $5 million |
| Calendar year net sales >= $500 million | $25 million |
| Calendar year net sales >= $1 billion | $50 million |
| Calendar year net sales >= $1.5 billion | $75 million |
Mechanism, Clinical Context, and Competitive Landscape
SCY-770 is a novel, highly selective, direct AMPK activator designed to act on several underlying mechanisms of ADPKD by reducing cyst growth and disease progression. ADPKD is the leading genetic cause of end-stage renal disease, affecting approximately 140,000 patients in the U.S. Currently, only one treatment is approved: Otsuka's Jynarque (tolvaptan), which generated approximately $1.5 billion in U.S. sales in 2024 despite limited patient adoption due to safety, tolerability, and monitoring constraints (mandatory liver function monitoring, aquaretic side effects including polyuria and polydipsia).
The mechanistic differentiation is meaningful: tolvaptan is a vasopressin V2 receptor antagonist that reduces cyst fluid secretion but does not address the underlying cyst growth pathways, while SCY-770's AMPK activation is designed to directly suppress the proliferative and metabolic drivers of cyst expansion.
Poxel Corporate Context (Trust Structure)
The press release discloses a notable corporate structure: PXL770 was held by IPF (Trust 3) since September 30, 2024, which authorized the transfer back to Poxel SA for the sale. IPF will receive 75% of all amounts paid by Scynexis, which will be allocated to debt repayment. However, IPF has agreed that a portion of the upfront (up to EUR 3.75 million) and the two clinical milestone payments will be set aside for Poxel's future financing needs under the Tranche D PDR documentation.
This trust structure means Poxel's effective net economics from the deal are significantly reduced: roughly 25% of the upfront and early milestones, with 75% flowing to creditors. The deal is framed as part of Poxel's continuation plan, with the company now focusing on TWYMEEG (imeglimin, marketed in Japan by Sumitomo Pharma) and PXL065 (deuterium-stabilized R-pioglitazone for MASH).
Concurrent Scynexis $40 Million Private Placement
Simultaneously, Scynexis announced a $40 million private placement with certain new and existing institutional and accredited investors, with the potential for an additional $52.2 million if common warrants are fully exercised for cash (subject to stockholder approval). The PIPE provides the capital to fund the $8 million upfront payment and Phase 2 development of SCY-770.
Royalty financing relevance: moderate. The $196 million headline is heavily milestone-loaded and the asset is pre-Phase 2 in ADPKD. However, the orphan designation, patent protection through 2041, large addressable market ($1.5 billion Jynarque benchmark), and clear unmet need (tolerability-driven patient attrition from Jynarque) create a potentially attractive commercial profile. If Phase 2 proof-of-concept data are positive (H2 2027), the combination of orphan economics and mechanistic differentiation could make SCY-770 a candidate for royalty financing at the Phase 3 stage.
Upstream IP and Royalty Stack: Clean, but Creditor Liens Dominate
PXL770 was invented entirely by Poxel scientists (Daniel Cravo, Sophie Hallakou-Bozec, Sebastien Bolze) after the company's 2009 spin-out from Merck Serono. The composition-of-matter patent (US 9,284,329, priority June 2012) is assigned solely to Poxel SA with no academic co-assignees. Critically, no running royalties are owed to Poxel on net sales -- this is a milestone-only structure.
One residual risk: Poxel's 2009 spin-off agreement with Merck Serono was never fully disclosed publicly. While Poxel pays Merck a confirmed 8% royalty on Imeglimin (TWYMEEG) sales, no public filing extends this obligation to PXL770. The earlier Merck Patent GmbH thienopyridone AMPK patents (2008 priority) are in the same chemical class, but PXL770 was patented independently. Poxel's 2024 annual report was never published due to creditor negotiations, leaving this an unresolved gap for Scynexis's diligence team.
Cyclerion Therapeutics / Korsana Biosciences: Reverse Merger with ~$380 Million Private Financing (April 1)
On April 1, Cyclerion Therapeutics (NASDAQ: CYCN) and private-company Korsana Biosciences announced an all-stock reverse merger under which the combined entity will operate as Korsana and trade on Nasdaq under the ticker KRSA. The transaction is accompanied by a concurrent ~$380 million gross private financing, making this one of the largest reverse-merger financings in biotech in 2026.
Deal Structure
| Term | Detail |
|---|---|
| Structure | All-stock reverse merger; Korsana is the surviving operating business |
| Ticker / name post-close | KRSA / Korsana Biosciences |
| Cyclerion shareholder ownership | Approximately ~1.5% of combined entity at close (subject to net-cash adjustment) |
| Concurrent private financing | ~$380 million gross proceeds |
| Financing lead investors | Fairmount and Venrock Healthcare Capital Partners |
| Syndicate | General Atlantic, TCGX, Forbion, Wellington Management, Commodore Capital, RA Capital, RTW Investments, Vivo Capital, Janus Henderson, Foresite Capital, J.P. Morgan Life Sciences Private Capital, SR One, Sanofi Ventures |
| Placement agents (financing) | Jefferies, TD Cowen, Stifel, UBS Investment Bank, Wedbush Securities |
| Korsana strategic advisor | Wedbush (exclusive) |
| Korsana legal counsel | Gibson Dunn & Crutcher LLP |
| Placement agent counsel | Cooley LLP |
| Cyclerion financial advisor | Gemini Valuation |
| Cyclerion legal counsel | Ropes & Gray LLP |
| Closing conditions | SEC Form S-4 registration statement effectiveness; HSR waiting period expiration; shareholder votes |
Context
Korsana is a private biosciences company; its pipeline and lead programs were not disclosed in detail in the merger announcement. The investor syndicate — which spans specialist healthcare funds (Fairmount, RA Capital, RTW, Foresite), crossover investors (Wellington, Janus Henderson), and corporate strategics (Sanofi Ventures, J.P. Morgan Life Sciences Private Capital) — signals a program of meaningful clinical stage and near-term data expectations. The breadth of the syndicate and the $380 million raise size are consistent with a Phase 2/3-stage asset requiring significant capital for a pivotal readout or commercial preparation.
Cyclerion shareholders receive approximately 1.5% of the combined entity, reflecting the dominant value of Korsana's pipeline relative to Cyclerion's legacy soluble guanylate cyclase (sGC) platform assets (formerly spun out from Ironwood Pharmaceuticals). Cyclerion's inclusion primarily provides a Nasdaq listing vehicle and some residual net cash.
Royalty financing relevance: watch list. With $380 million in committed capital and a blue-chip investor syndicate, Korsana's lead program will likely have sufficient runway for a major clinical readout. If data are positive, this becomes a synthetic royalty candidate at the Phase 3-to-NDA inflection — the classic entry point for royalty financing on private or newly public companies needing non-dilutive capital to fund a commercial launch.
Upstream Royalty Stack: Cyclerion sGC Assets Carry Ironwood Legacy Obligations
Korsana's own pipeline and royalty obligations cannot be assessed until the S-4 registration statement is filed and the pipeline disclosed. However, Cyclerion's legacy sGC stimulator assets (praliciguat, olinciguat, crizanlokast, IW-6463) carry a royalty obligation to Ironwood Pharmaceuticals from the 2019 spin-off: Cyclerion's 10-K discloses tiered royalties to Ironwood in the low-to-mid single digits (~2–5%) on net sales of any commercialized sGC product. These obligations transfer with Cyclerion's assets but are largely academic given Korsana's pipeline will be the operative commercial business, likely unrelated to sGC biology. The combined entity's material royalty obligations will be determined by Korsana's licensing arrangements, which remain undisclosed.
Seismic Pharma: Newco Formation with Windtree Heart Failure Assets (March 30)
On March 30, Seismic Pharma launched as a new company with a heart failure portfolio acquired from Windtree Therapeutics (formerly Discovery Labs). The newco was formed with financing led by Panacea Capital, though the acquisition price and financing size were not disclosed.
Seismic's lead program is istaroxime, a Phase 3-ready, first-generation calcitrope for cardiogenic shock with extensive clinical data demonstrating improved hemodynamic stability and cardiac function without the safety concerns associated with traditional inotropes. The company also holds next-generation calcitrope compounds.
Windtree's prior clinical work included the SEISMiC series of Phase 2 studies in SCAI Stage B and C cardiogenic shock, with an interim data review in Q3 2025 informing Phase 3 readiness. Lee's Pharmaceutical holds Greater China licensing rights. The Seismic board includes members with experience in successful heart failure programs.
SV Health Investors: Acquisition of EpiVax (April 2)
SV Health Investors (SVHI), a healthcare-focused private investment firm with over $2.0 billion in assets under management and offices in Boston and London, announced on April 2 the acquisition of EpiVax, Inc., a Providence, Rhode Island-based bioanalytical contract research organisation specialising in immunogenicity risk assessment and consulting services for pharmaceutical and biotech companies. Financial terms were not disclosed. Founded in 1998, EpiVax serves clients across the biologics development lifecycle with computational immunology tools and in vitro testing capabilities. SVHI described the transaction as a new platform investment within its pharma services strategy, which has previously included investments in Adimab, Clario, Celerion, and Leiters. The deal fits the broader trend of private equity consolidation of pharmaceutical services businesses with recurring revenue and embedded client relationships.
Merck KGaA (MilliporeSigma): JSR Life Sciences Chromatography Business Acquisition Closes (April 1)
Merck KGaA (operating as MilliporeSigma in the U.S.) completed the acquisition of JSR Life Sciences' chromatography business on April 1, following the definitive agreement signed in October 2025. The transaction adds JSR's Amsphere™ Protein A resins and advanced chromatography capabilities to MilliporeSigma's Process Solutions portfolio, along with more than 50 Belgium-based employees. Financial terms were not disclosed. The deal strengthens Merck KGaA's position in downstream bioprocessing, particularly Protein A-based monoclonal antibody purification — a critical infrastructure component for the growing biologics and biosimilar manufacturing sector. While this is a life sciences tools transaction rather than a drug deal, it is noted for completeness given its relevance to the CDMO and bioprocessing supply chain that underpins royalty-generating biologics manufacturing.
Eli Lilly / Insilico Medicine: $2.75 Billion AI Drug Discovery Collaboration (Formal Announcement, March 29)
This deal was previewed in W13 based on a Financial Times report (March 29) and the FTC HSR Early Termination filing (March 26). The formal joint announcement from Insilico Medicine on March 29 confirmed materially expanded terms versus the initial FT report of a $2 billion single-asset GLP-1 license.
On March 29, Insilico Medicine (HKEX: 3696) announced a global R&D collaboration and licensing agreement with Eli Lilly worth up to $2.75 billion, an increase from the $2 billion reported by the FT earlier that day. The deal includes an $115 million upfront payment plus development, regulatory, and commercial milestones, and tiered royalties on future net sales.
What Changed from the W13 Preview
| Term | W13 (FT report) | W14 (formal announcement) |
|---|---|---|
| Total deal value | Up to $2 billion | Up to $2.75 billion |
| Scope | Single GLP-1 diabetes asset | Portfolio of novel oral therapeutics across multiple therapeutic areas + joint R&D programs on Lilly-selected targets |
| Upfront | $115 million | $115 million (confirmed) |
| Royalties | Not disclosed | Tiered royalties on net sales (rates undisclosed) |
| Rights | Not specified | Lilly receives exclusive worldwide license for development, manufacturing, and commercialization |
The expanded scope transforms this from a single-asset license into a platform-level partnership. Lilly gains access to Insilico's Pharma.AI suite (Biology42 for target ID, Chemistry42 for molecular design, Science42 for clinical prediction) alongside the preclinical oral therapeutics portfolio. Insilico CEO Alex Zhavoronkov suggested the cardiometabolic angle, while STAT News confirmed Insilico's pipeline page was updated to show a GLP-1-targeting candidate out-licensed to an undisclosed partner.
No financial or legal advisors were disclosed for either party. The deal was announced via HKEX voluntary announcement (Insilico) and press release. See W13 for comprehensive analysis of the Lilly-Insilico relationship timeline, HSR filing structure, Insilico's partnership portfolio, and upstream royalty exposure.
Upstream IP and Royalty Stack: Clean
A review of Insilico's HKEX IPO prospectus and patent filings reveals an unusually unencumbered IP position. The Pharma.AI platform (PandaOmics, Chemistry42, InClinico) was built internally starting in 2014-2016 and is protected by 700+ patents or applications globally. Despite founder Alex Zhavoronkov's academic connections to Johns Hopkins (MS in Biotechnology), Moscow State University (PhD), and HKUST, no academic IP licenses creating upstream royalty obligations were identified. NVIDIA's relationship is a commercial hardware/software arrangement through the Inception program, not an IP encumbrance. The absence of upstream royalty layers on the licensed assets means Lilly's commercial economics on any resulting products would be subject only to Insilico's tiered royalties, with no additional stacking from academic or platform licensors.
Royalty Pharma / Johnson & Johnson: $500 Million R&D Co-Funding for JNJ-4804
On March 30, Royalty Pharma (NASDAQ: RPRX) announced a $500 million R&D co-funding agreement with Johnson & Johnson to advance JNJ-4804 (JNJ-78934804), a co-antibody therapy simultaneously blocking interleukin-23 (IL-23) and tumor necrosis factor (TNF) pathways, through Phase 2 clinical development across multiple autoimmune indications.
Deal Structure
| Term | Detail |
|---|---|
| Funder | Royalty Pharma (NASDAQ: RPRX) |
| Developer | Johnson & Johnson (NYSE: JNJ) |
| Asset | JNJ-4804, dual-pathway co-antibody (IL-23 + TNF blockade) |
| Commitment | Up to $500 million deployed across 2026-2027 |
| Return structure | Future royalty streams on commercial sales (specific rates not disclosed) |
| Legal advisor (RPRX) | Goodwin Procter LLP |
| Clinical stage | Active Phase 2 trials in UC (DUET-UC), Crohn's (DUET-CD), and PsA (AFFINITY) |
Mechanism and Clinical Context
JNJ-4804 combines the biology of guselkumab (Tremfya) and golimumab (Simponi) into a single co-antibody construct that simultaneously blocks IL-23 and TNF, two validated but mechanistically distinct inflammatory pathways. Prior data from the VEGA UC study demonstrated 47.9% clinical remission at Week 38 for combination induction followed by guselkumab maintenance, versus 31.0% for guselkumab alone and 20.8% for golimumab alone.
The AFFINITY PsA study results, published March 25, missed the primary endpoint of Week 24 minimal disease activity but showed a higher ACR50 response rate for the combination approach. The UC and Crohn's programs are considered the lead indications with the strongest efficacy signal.
Royalty Financing Relevance: Very High
This deal is structurally significant for the royalty financing market on multiple dimensions. It represents Royalty Pharma's latest "R&D co-funding" transaction, a model where RPRX provides non-dilutive development capital in exchange for future royalty economics on commercial sales. The $500 million commitment is the second-largest R&D co-funding deal RPRX has announced in 2026, following the $275 million AVLAYAH agreement with Denali Therapeutics.
Pablo Legorreta, RPRX's CEO, positioned the deal within the company's immunology heritage. The key diligence question for royalty investors, as noted by LucidQuest Ventures, is the degree of downside protection and operating control Royalty Pharma retains relative to simply funding a J&J-controlled development program. The dual-pathway biology also carries differentiation risk: if either the IL-23 or TNF component proves unnecessary or problematic in combination, the asset's commercial profile could narrow.
The deal validates continued institutional appetite for autoimmune royalty exposure, coming in the same week as the Galapagos/Gilead 20-23% royalty structure on the BCMAxCD3 autoimmune TCE space and following Sanofi's $1.23 billion Kali Therapeutics TCE license in W13.
Upstream IP and Royalty Stack: RPRX Holds Two Layers
A critical distinction emerged from the research: JNJ-4804 is a co-antibody therapy (co-formulating two existing marketed antibodies), not a true bispecific. This means it inherits the full upstream IP obligations of both component antibodies.
Guselkumab was generated using MorphoSys's proprietary HuCAL GOLD phage display technology. MorphoSys (now a Novartis subsidiary) receives tiered mid-single-digit royalties (~3-5%) on Tremfya net sales. Since June 2021, 100% of these royalties flow to Royalty Pharma under the $1.425 billion Strategic Funding Partnership with MorphoSys.
Golimumab was generated using Medarex's UltiMAb transgenic mouse platform. Bristol-Myers Squibb, which acquired Medarex in 2009 for $2.4 billion, receives royalties at an estimated low-to-mid single digits (~2-5%).
This creates a striking situation: Royalty Pharma effectively holds two layers of economic interest in JNJ-4804 -- the new synthetic royalty from the $500 million co-funding deal, plus 100% of the existing MorphoSys/HuCAL royalty on the guselkumab component. No bispecific antibody platform royalties (Genmab DuoBody, Zymeworks Azymetric) apply because JNJ-4804 is a co-antibody, not a bispecific. No academic institution licenses were identified for either component.
| Layer | Recipient | Est. Rate | Status |
|---|---|---|---|
| RPRX synthetic royalty (new) | Royalty Pharma | Est. 3-6% tiered | New (March 2026) |
| HuCAL/guselkumab platform | MorphoSys -> 100% to RPRX | ~3-5% tiered | Active; RPRX double-dip |
| UltiMAb/golimumab platform | Bristol-Myers Squibb | Est. 2-5% | Active |
| Total estimated royalty outflow from J&J | ~8-16% |
Galapagos / Gilead: Binding Framework Agreement for Ouro Medicines Collaboration (March 31)
On March 31, Galapagos NV (Euronext/NASDAQ: GLPG) and Gilead Sciences announced the execution of a binding Framework Agreement formalizing the collaboration structure previewed in W13's Gilead/Ouro Medicines acquisition coverage. The underlying asset — the BCMAxCD3 T-cell engager acquired from Ouro Medicines — has received the INN gamgertamig, confirming its regulatory identity as a distinct molecular entity.
What the Binding Agreement Confirms
The final terms closely track the W13 disclosure but add important detail on the broader portfolio and cash deployment provisions:
| Term | Detail |
|---|---|
| Galapagos upfront cost share | 50% of $1.675 billion (~$837.5 million) |
| Galapagos milestone exposure | 50% of up to $500 million contingent milestones |
| Pre-registrational development costs | 100% Galapagos |
| Registrational costs | 50/50 |
| Galapagos royalty on net sales | Tiered 20-23% |
| Registrational trial milestones | Up to $100 million payable to Galapagos upon Gilead initiation |
| Additional preclinical programs | BCMAxCD19xCD3 TCE + 3 preclinical autoimmune programs transferred to Galapagos |
| Gilead option on preclinical programs | $75 million per program to opt into 50/50 profit split |
| KeyMed cost sharing | Galapagos funds 25% of milestones and 50% of royalties owed to KeyMed |
| OLCA waiver | Galapagos may deploy $500 million independently, including $150 million for buybacks |
Advisors
| Role | Firm |
|---|---|
| Galapagos financial advisor | Morgan Stanley |
| Galapagos legal counsel | Paul, Weiss, Rifkind, Wharton & Garrison LLP and Linklaters LLP |
| Independent financial expert | MTS Health Partners (required under Belgian Art. 7:97 BCCA related-party procedure, as Gilead owns 25.35% of Galapagos) |
| Gilead advisors | Not disclosed in the binding agreement announcement |
Galapagos separately noted that its planned separation into two publicly traded entities remains on track, meaning the Ouro-related assets and royalty economics could ultimately reside in a dedicated entity.
Upstream IP and Royalty Stack: Total Commercial Burden ~24–29%
The KeyMed royalty rate is not publicly disclosed. Based on comparable China-to-West BCMAxCD3 and bispecific antibody out-licenses in 2023–2025 (including KeyMed's other disclosed transactions), the KeyMed royalty to Gilead is estimated at mid-single digits (~4–6%) on worldwide net sales. Galapagos funds 50% of this obligation (~2–3% net contribution). The academic IP for BCMA as a target (Institut Gustave Roussy, University of Southampton) is broadly licensed and not identified as a material encumbrance on gamgertamig specifically.
| Layer | Direction | Recipient | Est. Rate |
|---|---|---|---|
| KeyMed Biosciences | Outflow from Gilead | KeyMed | ~4–6% |
| Galapagos funds 50% of KeyMed | Galapagos contribution | KeyMed (via Galapagos) | ~2–3% of net sales |
| Galapagos synthetic royalty | Inflow to Galapagos | Galapagos NV | 20–23% tiered |
| Total royalty outflow from commercial sales | ~24–29% of net sales |
The 20–23% Galapagos royalty is exceptional for an autoimmune biologic — typical immunology royalties run 5–12%. It reflects Galapagos's $837.5M co-development contribution and the first-in-class BCMAxCD3 autoimmune mechanism. This elevated royalty burden would be a significant consideration in any future synthetic royalty financing layered on top of the existing stack.
Merck / Infinimmune: $838 Million Antibody Discovery Collaboration (March 31)
On March 31, Infinimmune announced a research and development collaboration with Merck (NYSE: MRK) worth up to approximately $838 million in aggregate milestones, with an undisclosed upfront payment. Merck gains exclusive development and commercialization rights to antibodies discovered under the collaboration.
Deal Structure
| Term | Detail |
|---|---|
| Partners | Merck (NYSE: MRK) and Infinimmune (private) |
| Platform | Infinimmune's Anthrobody® discovery platform + GLIMPSE™ antibody language model |
| Target areas | Multiple undisclosed targets including IL-22 and IL-13 (atopic dermatitis, IgA nephropathy, ulcerative colitis) |
| Upfront | Undisclosed |
| Milestones | Up to approximately $838 million per program |
| Rights | Merck receives exclusive worldwide development and commercialization rights |
Context
Infinimmune, based in Alameda, California, had raised approximately $22 million prior to this deal. The company's Anthrobody platform is designed to generate fully human antibodies from diverse B-cell repertoires, with the GLIMPSE language model providing sequence-level optimization. Discussions between the parties reportedly began in December 2024. Merck's rationale appears to be broadening its immunology pipeline beyond the Keytruda franchise, particularly in atopic dermatitis and inflammatory bowel disease — two large markets where Keytruda has limited relevance but where biologics competition is intensifying (Sanofi/Regeneron's dupilumab, AstraZeneca's lebrikizumab, and multiple anti-IL-13 programs).
Royalty financing relevance: low near-term, watch list. Infinimmune's assets are pre-clinical. The $838 million milestone figure is a ceiling across potentially multiple programs, not a single asset valuation. However, if Merck advances one or more Anthrobody-derived candidates into Phase 2, the IP structure (Infinimmune as sole inventor, no academic co-assignees identified) would make any resulting product a relatively clean royalty target. The deal is included here as a precedent for AI-antibody platform licensing economics in 2026.
Upstream IP and Royalty Stack: Platform Appears Clean
A USPTO patent assignment search identifies four Infinimmune patent families filed 2021–2024, all assigned solely to Infinimmune, Inc. Named inventors include founders with prior affiliations at UC Berkeley, Genentech, and Scripps Research Institute — the UC Berkeley connection raises a theoretical Bayh-Dole question if any research used federal funding or UC facilities, but the patents contain no federal funding statements, suggesting purely private development. The GLIMPSE language model carries no identified third-party IP obligations on architecture or training data. Conclusion: clean IP stack, though full confirmation will depend on Merck's diligence findings.
Frontier Medicines / LG Chem — FMC-220 Ex-China License (April 1)
On April 1, Frontier Medicines (private, South San Francisco/Boston) granted LG Chem, Ltd. (KRX: 051910) an exclusive worldwide license to develop and commercialize FMC-220, a first-in-class covalent p53 Y220C activator, outside of Greater China. Frontier retains full ownership and control in Greater China.
| Term | Detail |
|---|---|
| Licensor | Frontier Medicines Corporation (private) |
| Licensee | LG Chem, Ltd. (KRX: 051910), Life Sciences division |
| Asset | FMC-220, first-in-class covalent p53 Y220C activator |
| Territory (LG Chem) | Worldwide excluding Greater China |
| Territory (Frontier) | Greater China (retained, full ownership) |
| Upfront | Undisclosed |
| Milestones | Clinical, regulatory, and commercial (undisclosed) |
| Royalties | Mid-single-digit to double-digit on net sales (tiered) |
| Co-development option | Frontier retains option to partially fund confirmatory trial for enhanced financial participation |
| Development responsibility | LG Chem leads regulatory filings, clinical development, manufacturing, and commercialization in licensed territories |
| Clinical stage | Pre-Phase 1; Phase 1 planned in U.S. and Korea in 2026 |
| Initial indication | Ovarian cancer (highest Y220C prevalence), expanding to other solid tumors |
FMC-220 targets the TP53 Y220C mutation, the most common structural p53 mutation outside the DNA-binding surface, occurring in approximately 1% of all solid tumors — an estimated 100,000–125,000 new cancer cases annually worldwide. Ovarian cancer carries the highest Y220C frequency, followed by endometrial, breast, and lung cancers. The Y220C mutation destabilizes the p53 protein, impairing its tumor-suppressive functions.
FMC-220 is mechanistically differentiated from the leading clinical competitor, PMV Pharma's rezatapopt (PC14586), a non-covalent p53 Y220C reactivator currently in the pivotal Phase 2 PYNNACLE basket trial. FMC-220's covalent binding mechanism provides prolonged target residence time, persistent promoter engagement, and sustained p53 transcriptional activation even after treatment cessation — properties that non-covalent approaches cannot replicate. Critically, FMC-220 activates cancer cell-death pathways and remains highly active in the presence of elevated MDM2 levels, a resistance driver in RAS-mutant tumors. This is a material differentiator: KRAS co-mutations are present in approximately 22% of patients with Y220C-mutant cancers, and the PYNNACLE trial restricts enrollment to KRAS wild-type patients only. In preclinical studies, FMC-220 delivered tumor regressions including complete responses across CDX and PDX models regardless of histology or co-mutations.
FMC-220 was discovered using Frontier's proprietary platform integrating chemoproteomics, covalent fragment-based discovery, and machine learning. It is the second development candidate from the Frontier Platform, following FMC-376 (dual ON/OFF KRASG12C inhibitor, Phase 1/2 PROSPER trial). Frontier has raised approximately $236 million to date (Series A–C), with investors including Deerfield Management, RA Capital, Droia Ventures, MPM Capital, DCVC Bio, and notably Galapagos NV as a strategic investor in the $80 million Series C (February 2024) — a cross-reference to the Galapagos/Gilead Framework Agreement covered earlier in this issue. LG Chem's Life Sciences division plans to initiate Phase 1 in the U.S. and Korea in 2026, focusing initially on ovarian cancer before expanding to other Y220C-harboring solid tumors.
Royalty financing relevance: low near-term, watch list. The mid-single-digit to double-digit royalty range suggests an estimated ~5–6% at early sales tiers, rising to 10–12%+ at higher thresholds, consistent with comparable preclinical oncology out-licenses from U.S. platform companies to Korean pharmaceutical partners. FMC-220 is pre-Phase 1 targeting a ~1% mutation frequency, limiting near-term addressable market size. However, if Phase 1 data confirm the covalent mechanism's clinical superiority over non-covalent rezatapopt — particularly in KRAS co-mutant tumors — the precision oncology basket trial framework could support accelerated development. At that inflection, Frontier's retained China rights and royalty income from LG Chem could become candidates for royalty monetization.
Upstream IP and Royalty Stack: Appears Clean, UC Berkeley Bayh-Dole Question
FMC-220 was discovered internally using the Frontier Platform. Frontier's co-founders include Daniel K. Nomura, Ph.D. and Roberto Zoncu, Ph.D., both UC Berkeley professors, raising a theoretical Bayh-Dole Act question if any foundational platform development used federal funding or UC facilities. However, Frontier's patents contain no federal funding disclosure statements, and the company consistently describes the platform as proprietary and wholly owned, suggesting purely private development. No third-party platform license, academic royalty obligation, or upstream IP encumbrance on FMC-220 was identified in public filings or patent assignment records.
| Layer | Direction | Party | Est. Rate |
|---|---|---|---|
| LG Chem royalty to Frontier | Inflow (ex-China sales) | Frontier Medicines | ~5–12% tiered (est.) |
| Frontier retained China rights | Direct economics | Frontier Medicines | 100% |
| Academic / platform IP | None identified | — | 0% |
| Total upstream royalty burden on LG Chem | ~5–12% to Frontier only |
The absence of upstream IP stacking — no academic licenses, no platform technology royalties, no co-inventor obligations — makes FMC-220 a structurally clean asset from LG Chem's perspective. This contrasts with competing p53 programs where academic IP from structural biology research (e.g., the MRC Laboratory of Molecular Biology, Cambridge, where the Y220C druggable pocket was first characterized by Alan Fersht's group) could generate upstream royalty obligations.
Clinical Data and Conference Readouts
ACC.26 (March 29–30, New Orleans)
United Therapeutics: TETON-1 Phase 3 Success for Tyvaso in IPF (March 30)
On March 30, United Therapeutics (NASDAQ: UTHR) reported that its Phase 3 TETON-1 study of Tyvaso (nebulized treprostinil) in idiopathic pulmonary fibrosis (IPF) met its primary endpoint with an absolute FVC improvement of +130.1 mL versus placebo at Week 52 (Hodges-Lehmann estimate; 95% CI: 82.2-178.1 mL; p<0.0001).
| Parameter | TETON-1 | TETON-2 (Sep 2025) | Integrated (TETON-1 + TETON-2) |
|---|---|---|---|
| Primary endpoint (FVC mL vs placebo) | +130.1 mL | +95.6 mL | +111.8 mL |
| p-value | <0.0001 | <0.0001 | <0.0001 |
| Patients on background antifibrotic | 75.4% | ~74% | ~75% |
| Clinical worsening | Significant reduction | Significant reduction | Significant reduction |
| DLCO (diffusion capacity) | Improved | Not significant | Improved |
| Overall survival | Favorable trend (NS) | Favorable trend (NS) | Favorable trend (NS) |
The +130 mL FVC result exceeded TETON-2 and establishes Tyvaso as the most effective anti-fibrotic intervention measured in a Phase 3 IPF trial. United Therapeutics plans an sNDA submission by end of summer 2026 with priority review sought. UTHR stock surged approximately 16% in premarket trading to ~$609.
IPF affects over 100,000 Americans, with current therapies (nintedanib, pirfenidone) providing only modest benefit (+50-75 mL FVC preservation). Tyvaso would be the first inhaled anti-fibrotic and the first therapy to address the fibrotic, vascular, and inflammatory pathways simultaneously. Jefferies estimates the IPF market opportunity at $5-10 billion.
Upstream Royalty Stack: MannKind's 10% Applies to Tyvaso DPI Only — Not to the Nebulized Formulation Used in TETON
Treprostinil's original IP traces to The Upjohn Company, with rights passing through Pharmacia & Upjohn and Glaxo Wellcome to United Therapeutics. Both historical royalties have expired: the Pfizer/Pharmacia 4% royalty ended approximately May 2012, and the GSK/Glaxo Wellcome 10% royalty expired in October 2014. Per UT's most recent 10-K: the company has no remaining royalty obligations on nebulized Tyvaso or Remodulin.
The sole remaining royalty on Tyvaso DPI is the MannKind Corporation 10% royalty on net sales, established under a September 2018 worldwide exclusive license for MannKind's Technosphere technology and Dreamboat device. In January 2024, MannKind sold a 1% royalty interest to Sagard Healthcare for $150 million (with up to $50 million in sales milestones, royalty period through December 31, 2042), retaining 9%.
Critical distinction for royalty investors: The TETON-1 and TETON-2 studies used nebulized Tyvaso (treprostinil) Inhalation Solution — not Tyvaso DPI. United Therapeutics' press releases explicitly state that Tyvaso DPI is not being evaluated in the TETON program.
The sNDA planned for submission by end of summer 2026 is for nebulized Tyvaso in IPF. Any Tyvaso DPI approval for IPF would require additional bridging studies with uncertain timelines.
This means the massive IPF revenue opportunity — analyst estimates range from $1.5 billion by 2030 (S&P Global) to $5–10 billion peak (Jefferies) — will initially accrue entirely to nebulized Tyvaso, on which MannKind and Sagard earn zero royalty.
Tresmi threat to existing Tyvaso DPI royalties: On February 25, 2026, United Therapeutics CEO Martine Rothblatt unveiled Tresmi, a proprietary soft-mist inhaler formulation of treprostinil that reduces coughing (the primary DPI side effect) by up to 90%. UT plans to file Tresmi for PAH and ILD approval in 2026 with launch in 2027. MannKind's stock fell 38% on the Tresmi news. Tresmi threatens Tyvaso DPI not only in IPF but across existing PAH/PH-ILD indications as well.
Orenitram and Remunity carry separate royalties (Supernus and DEKA Research, respectively) that do not apply to either Tyvaso formulation.
ACC.26 Late-Breaking Presentations (March 29-30, New Orleans)
The American College of Cardiology annual meeting produced several presentations with significant commercial implications:
VESALIUS-CV (evolocumab, Amgen): Prespecified subgroup analysis showed evolocumab reduced first MACE by 31% in diabetic patients without significant atherosclerosis, a potential practice-changing extension of PCSK9 inhibition into primary prevention populations that could substantially expand Repatha's addressable market. Published simultaneously in JAMA.
Royalty context: No upstream royalty obligations to UT Southwestern (Hobbs/Cohen) were identified — their contribution was target validation, not the antibody itself. Amgen's broad PCSK9 genus patents were invalidated by the Supreme Court in 2023. Repatha carries no identified royalty burden.
SCOUT-HCM (mavacamten/Camzyos, BMS): The first study of a cardiac myosin inhibitor in patients under 18 met its primary endpoint with a -48.0 mm Hg difference in Valsalva LVOT gradient versus placebo (p<0.0001). Published simultaneously in NEJM. Supports a potential adolescent label expansion for Camzyos.
Royalty context: MyoKardia proactively eliminated Sanofi's 5-10% tiered U.S. royalty through an $80 million buyback in July 2019, before the $13.1 billion BMS acquisition. Camzyos's co-founders (James Spudich/Stanford, Leslie Leinwand/CU Boulder) contributed founding equity, not ongoing royalty-bearing licenses. Current royalty burden appears minimal to zero.
CADENCE (sotatercept/Winrevair, Merck): Phase 2 proof-of-concept showed a significant -1.02 Wood unit reduction in PVR at the 0.3 mg/kg dose (p=0.004) in combined post-/pre-capillary pulmonary hypertension with HFpEF. Guggenheim estimates approval for CpcPH-HFpEF could double Winrevair's commercial opportunity. However, a lack of clear dose-response (lower dose stronger than higher) drew scrutiny. Merck plans to advance to Phase 3.
Royalty context: Winrevair carries one of the heaviest royalty burdens among major cardiopulmonary assets. Under the 2017 Acceleron-Celgene amendment, BMS (as Celgene successor) receives royalties in the low-twenties percentage (~20-23%) on PH field net sales. The Salk Institute receives low single-digit royalties on worldwide net sales under a 2010 exclusive license for the original ActRIIA/ActRIIB receptor cloning. Combined aggregate royalty burden is estimated at ~21-25% — a significant consideration for royalty investors, given projected peak sales of $2-5 billion.
ESSENCE-CTA (olezarsen, Ionis): The coronary CTA substudy delivered a negative result: olezarsen did not significantly reduce non-calcified coronary plaque volume at 12 months despite approximately 60% triglyceride reduction and 15% ApoB lowering. This raises questions about whether short-term TG lowering translates to structural plaque benefit.
CORALreef AddOn (enlicitide, Merck): Phase 3 durability data for Merck's potential first oral PCSK9 inhibitor, supporting anticipated regulatory submission.
ALL-RISE (CathWorks FFRangio): Landmark trial showed AI-guided coronary physiology assessment met non-inferiority to invasive pressure wire for PCI guidance. Published simultaneously in NEJM.
CHAMPION-AF (WATCHMAN FLX, Boston Scientific): The landmark 3,000-patient trial showed Boston Scientific's WATCHMAN FLX left atrial appendage closure device met all primary and secondary endpoints versus NOACs for stroke prevention in non-valvular AF, with a 45% relative reduction in non-procedural bleeding. Published simultaneously in NEJM. The data expand the commercial case for LAAC as first-line AF stroke prevention.
PROTECT H2H (Emboliner, Emboline): The first randomized IDE trial of embolic protection in TAVR to meet all primary and secondary endpoints, including superiority for debris capture. Presented as a late-breaking clinical trial at ACC.26 on March 29.
HI-PEITHO (EKOS, Boston Scientific): The Phase 3 trial demonstrated that EKOS ultrasound-assisted catheter-directed thrombolysis plus anticoagulation was superior to anticoagulation alone in intermediate-high-risk pulmonary embolism: primary endpoint event rate 4.0% vs. 10.3% (61% relative reduction, p=0.005), with no intracranial bleeds in the device arm. Published simultaneously in NEJM. The result substantially strengthens the commercial case for catheter-directed thrombolysis in an indication with limited prior Level 1 evidence.
STEMI-DTU (Impella, Abiomed/J&J): Left ventricular unloading with Impella prior to primary PCI did not reduce infarct size or improve clinical outcomes in anterior STEMI without cardiogenic shock, and was associated with higher rates of bleeding and vascular complications versus standard care. A significant negative result for Impella's pre-shock indication expansion narrative.
HOST-EXAM 10-year follow-up: Long-term data from the Korean HOST-EXAM trial continued to support clopidogrel monotherapy over aspirin monotherapy as the preferred antiplatelet strategy beyond one year post-PCI, with persistent reduction in ischemic events and bleeding over a decade of follow-up.
HRS/BHB-1893 (Hengrui / Braveheart Bio, cardiac myosin inhibitor, oHCM): Hengrui Pharma and Braveheart Bio presented Phase 2 results for HRS-1893, a selective cardiac myosin inhibitor, in obstructive hypertrophic cardiomyopathy as Featured Clinical Research at ACC.26 on March 30.
In 42 patients over 12 weeks, complete Valsalva LVOT gradient response (<30 mmHg) ranged from 50% to 86% across dose groups, with onset as early as Day 5. At Week 39 of the open-label extension, complete response reached 88%.
Critically, mean LVEF decline was only 1.8–2.7% with no patient falling below 55% — a potential best-in-class safety signal versus mavacamten (Camzyos) and aficamten, which carry LVEF reduction boxed warnings or monitoring requirements. No treatment discontinuations due to adverse events were reported.
HRS-1893 is licensed to Braveheart Bio (launched November 2025 with a $185 million Series A led by a16z Bio+Health, Forbion, and OrbiMed) for all territories outside Greater China/Taiwan. Hengrui retains China rights and has an ongoing Phase 3 oHCM study (NCT07021976).
This is a separate Hengrui out-license from the Kailera Therapeutics obesity portfolio — see the Kailera S-1 section in Financing Events.
Royalty context: Braveheart Bio's license terms include $65 million upfront ($32.5 million cash + $32.5 million equity), up to $10 million in technology transfer milestones, and up to $1.013 billion in development and commercial milestones, plus undisclosed tiered royalties on ex-China net sales. If HRS-1893 reaches the pivotal stage with this safety profile, the oHCM market (currently ~$3.5 billion via Camzyos) and the Hengrui-to-Braveheart royalty stream could become candidates for royalty monetization.
SMART-DECISION (beta-blocker discontinuation post-MI): The SMART-DECISION trial (Strategic Medical Assessment for the Reconsidering of Treatment – Discontinuation of β-blocker in Stabilized Patients After Acute Myocardial Infarction), led by Joo-Yong Hahn (Samsung Medical Center, Seoul) and published simultaneously in the New England Journal of Medicine, enrolled 2,540 patients across 25 Korean centers.
The primary composite of death, recurrent MI, or HF hospitalization occurred in 7.2% (discontinuation) vs. 9.0% (continuation) — HR 0.80 (95% CI 0.57–1.13, p=0.001 for noninferiority) at median 3.1-year follow-up. Patients were stabilized (LVEF ≥40%, no HF) and randomized at median 4.7 years post-MI.
This is a distinct trial from the French ABYSS study (2024), which failed to meet noninferiority using softer endpoints with shorter time from MI. The result is practice-changing for a massive generic drug class but carries no direct royalty implications — all post-MI beta-blockers (metoprolol, carvedilol, bisoprolol, atenolol) are fully genericized.
Merck — CORALreef AddOn Phase 3 (March 30)
Merck presented Phase 3 CORALreef AddOn data for enlicitide decanoate, its investigational oral PCSK9 inhibitor, at ACC.26 on March 30. The results showed 64.6% LDL-C reduction from baseline at 8 weeks when added to background statin therapy, with 78.2% of patients reaching ≥50% LDL-C reduction to below 55 mg/dL — versus 2% for bempedoic acid alone, 8% for ezetimibe alone, and 20% for combination. Enlicitide also reduced Lp(a) by 26.2%. Data were published simultaneously in the Journal of the American College of Cardiology.
This is the third positive Phase 3 readout for enlicitide and positions the molecule as a potential first-in-class oral alternative to injectable PCSK9 inhibitors (Repatha, Praluent). The CORALreef AddOn data directly compete with the Amgen VESALIUS-CV primary prevention data for Repatha also presented at ACC.26 (covered in the original W14 filing). If enlicitide achieves NDA approval, the royalty implications for PCSK9 inhibitor franchises — including Regeneron's royalty streams from Praluent and potential royalties accruing from academic PCSK9 biology licenses — warrant monitoring.
Upstream IP and Royalty Stack: Ra Pharma / UCB Obligation Flagged
Enlicitide decanoate was discovered using Ra Pharmaceuticals' Extreme Diversity mRNA display platform under a 2013 collaboration, per a peer-reviewed ACS Medicinal Chemistry Letters article (PMC9465826). Ra's S-1 (2016) referenced a "Partnered Program — Oral macrocyclic peptide (Cardiovascular target)" with redacted licensing terms. Ra was acquired by UCB in 2020 for ~$2.1 billion, transferring any residual obligations.
Merck's subsequent medicinal chemistry optimization, formulation, and all clinical development were conducted internally, and Merck describes enlicitide as "Discovered and developed by MSD." However, UCB may hold low-to-mid single-digit royalty and/or milestone rights from the Ra collaboration — a potential upstream obligation that warrants diligence given enlicitide's multi-billion-dollar revenue trajectory.
UTSW/Hobbs/Cohen PCSK9 target validation patents do not cover the macrocyclic peptide modality, and in their 2024 Circulation editorial, Hobbs and Cohen report no commercial conflicts. Amgen's PCSK9 genus antibody patents were unanimously invalidated by the Supreme Court in 2023 and would not have extended to peptide approaches regardless.
If approved without material UCB obligations, Merck would capture commercial economics at a structurally cleaner position than competing PCSK9 antibody franchises.
BridgeBio — ATTRibute-CM Open-Label Extension, Month 54 (March 30)
BridgeBio Pharma presented Month 54 open-label extension data from the ATTRibute-CM study of acoramidis (Attruby) in ATTR cardiomyopathy at ACC.26 on March 30. The long-term data showed 44.7% lower all-cause mortality (p<0.001) and 49.3% lower cardiovascular mortality (p<0.001) for patients who initiated acoramidis at randomization versus those who started later (delayed-treatment arm). Data were published simultaneously in JAMA Cardiology.
These data extend the ATTRibute-CM efficacy story meaningfully and strengthen acoramidis's positioning against Pfizer's tafamidis (Vyndaquel/Vyndaqel) — currently the dominant standard of care in ATTR-CM with approximately $3.5 billion in annual global revenues. Pfizer holds ATTR-CM royalty exposure from academic TTR biology licenses (University of Coimbra/Scripps Research Institute); BridgeBio's acoramidis carries a lighter but non-zero upstream burden. Royalty investors tracking the ATTR-CM space should note the accumulating long-term superiority data as a potential catalyst for formulary share shifts in 2026–2027.
Upstream IP and Royalty Stack: Stanford License Confirmed; Scripps/Kelly Does Not Apply
Acoramidis was discovered at Stanford University through the SPARK translational program by Dr. Isabella Graef and Dr. Mamoun Alhamadsheh. Eidos Therapeutics (BridgeBio subsidiary) holds an Exclusive Patent License and Equity Agreement (effective April 10, 2016) under which Stanford receives low single-digit royalties (~1–3% estimated) on net sales plus milestone payments. BridgeBio acquired the remaining ~36.3% of Eidos in January 2021 at an implied ~$2.83 billion enterprise valuation.
The Scripps Research Institute / Jeffery Kelly tafamidis royalty does NOT extend to acoramidis. Acoramidis is a structurally distinct molecule discovered through a separate high-throughput screen. While both drugs stabilize the TTR tetramer, their chemical scaffolds and binding mechanisms differ. Patent assignments for acoramidis list Eidos/BridgeBio only, with no Scripps co-assignees.
BridgeBio has already executed multiple royalty monetization transactions on the acoramidis franchise:
- A $500 million royalty financing with Blue Owl/CPP Investments (January 2024; 5% worldwide net sales royalty capped at 1.9×)
- A $300 million partial European royalty monetization with HCRx/Blue Owl (September 2025; 60% of first $500 million annual Beyonttra European sales, capped at 1.45×)
BridgeBio receives inbound royalties from Bayer (low-thirties percentage, Europe) and Alexion/AstraZeneca (low double-digit, Japan). Attruby generated $362.4 million in U.S. net product revenue in FY2025, with a Q4 annualized run rate of approximately $584 million.
| Layer | Direction | Party | Est. Rate |
|---|---|---|---|
| Stanford University | Outflow | Stanford | ~1–3% |
| Blue Owl / CPP Investments | Outflow | Blue Owl | 5% (capped 1.9×) |
| HCRx / Blue Owl (Europe only) | Outflow | HCRx | 60% of first $500M EU sales (capped 1.45×) |
| Bayer (Europe) | Inflow | BridgeBio | Low-thirties % |
| Alexion/AstraZeneca (Japan) | Inflow | BridgeBio | Low double-digit % |
AAD 2026: Dermatology Late-Breaking Data (March 28–31)
The 2026 American Academy of Dermatology Annual Meeting in San Diego overlapped with W14 (running through March 31) and produced several Phase 3 readouts with near-term regulatory and royalty implications.
Alumis — ONWARD1/ONWARD2 (Envudeucitinib, TYK2 Inhibitor, Psoriasis)
Alumis (NASDAQ: ALMS) presented Phase 3 ONWARD1 and ONWARD2 data for envudeucitinib, a selective TYK2 inhibitor, in moderate-to-severe plaque psoriasis at AAD 2026 (March 28). Both co-primary endpoints were met: PASI 90 of 59.9% at Week 16 (ONWARD1) and 53.1% (ONWARD2), versus approximately 5% for placebo. An NDA submission is planned for H2 2026.
Envudeucitinib competes directly with Bristol-Myers Squibb's deucravacitinib (Sotyktu), currently the approved TYK2 inhibitor in psoriasis. The ONWARD program's PASI 90 rates are numerically superior to the POETYK PSO-1 data (53.6% at Week 16) that supported Sotyktu's approval. Alumis also has an NDA filed for envudeucitinib in systemic lupus erythematosus (SLE), pending PDUFA review.
Upstream IP and Royalty Stack: Milestone-Based, Not Royalty-Bearing
Envudeucitinib was acquired by Alumis through the purchase of FronThera U.S. Holdings in March 2021. SEC filings indicate the deal structure is milestone-based, not royalty-based: up to $120 million in aggregate milestones (approximately $60 million remaining after a $23 million payment in Q3 2024).
No ongoing royalty obligations to Hepagene or FronThera on net sales are disclosed in Alumis's 10-K or 10-Q filings. Foundational TYK2 kinase biology patents from the 1990s are largely expired, and envudeucitinib is structurally distinct from BMS's deucravacitinib (Sotyktu) with independent IP (38 FronThera-originated patents).
For royalty investors, the absence of a running sales royalty — only milestone payments — makes envudeucitinib a structurally attractive asset for synthetic royalty financing if approved, with substantially more headroom than initially estimated.
Takeda — Phase 3 (Zasocitinib, TYK2 Inhibitor, Psoriasis)
Takeda presented Phase 3 data for zasocitinib (TAK-279), its competing TYK2 inhibitor, at AAD 2026 (March 28). Phase 3 results showed PASI 90 of approximately 61.3% and 51.9% at Week 16 across two studies, versus ~5% placebo. Takeda acquired zasocitinib as part of its $4 billion acquisition of Nimbus Therapeutics in December 2023 — the single largest upfront acquisition in biotech at that time. An NDA filing is planned for FY2026. This data set is a critical commercial validation for the $4 billion Nimbus bet; see W13 for the Nimbus royalty stack analysis.
Upstream royalty: Schrödinger, Inc. holds confirmed rights to single-digit percentage royalties on commercial sales plus development and commercial milestones, reflecting its role as co-inventor via a 2010 Master Services Agreement with Nimbus. Schrödinger received approximately $147.2 million from the Takeda-Nimbus acquisition (reflecting its ~7.6% equity stake). No academic institution licenses were identified.
Incyte — STOP-HS1/2, 54-Week Data (Povorcitinib, JAK1 Inhibitor, Hidradenitis Suppurativa)
Incyte (NASDAQ: INCY) presented 54-week long-term data for povorcitinib in hidradenitis suppurativa (HS) at AAD 2026 (March 28). HiSCR50 response rates of up to 71.4% were observed at Week 54, with durable response maintained through the extended follow-up period. An NDA for povorcitinib in HS is under FDA review, with a PDUFA date expected in mid-2026. HS is a large and underserved dermatological market; AbbVie's bimekizumab (Bimzelx) and Boehringer Ingelheim's spesolimab (Spevigo) are among the recently approved biologics targeting the same patient population.
Upstream IP: Povorcitinib (INCB54707) was wholly owned and internally discovered by Incyte. No upstream royalties. Incyte is the licensor, having out-licensed Greater China rights to China Medical System Holdings in March 2024.
Biogen — AMETHYST Part A Phase 2 (Litifilimab, Cutaneous Lupus Erythematosus)
Biogen (NASDAQ: BIIB) presented Phase 2 AMETHYST Part A data for litifilimab in cutaneous lupus erythematosus (CLE) at AAD 2026 (March 28). The study met its primary endpoint: 14.7% of litifilimab-treated patients achieved a CLA-IGA-R score of 0–1 (clear or almost clear skin) versus 2.9% for placebo (p<0.05) at Week 16. Litifilimab holds Breakthrough Therapy Designation from the FDA for CLE. This is the second positive Phase 2 CLE study for the asset; Biogen has previously reported positive LILAC-1 data. The company is advancing discussions on Phase 3 design.
Upstream IP and Royalty Stack: In-House Discovery; Royalty Pharma R&D Co-Funding
Litifilimab was discovered and developed in-house by Biogen. Biogen consistently describes the compound as internally originated in its SEC filings. No INSERM or other academic upstream license on the BDCA2 target biology was identified in public filings.
However, Biogen executed a significant Royalty Pharma R&D co-funding deal in February 2025: up to $250 million over six quarters in exchange for regulatory milestones and mid-single-digit royalties on worldwide litifilimab sales if approved.
This RPRX layer — not a JPI license — is the primary identified royalty obligation. As litifilimab advances toward Phase 3 with Breakthrough Therapy Designation and two positive Phase 2 studies, the RPRX co-funding royalty will be the dominant upstream encumbrance for any additional synthetic royalty financing.
Sanofi — COAST Studies (Amlitelimab, OX40L Inhibitor, Atopic Dermatitis)
Sanofi presented Phase 3 data from the COAST program for amlitelimab, a non-depleting anti-OX40 ligand antibody, in moderate-to-severe atopic dermatitis across three studies during AAD 2026. The results were mixed and sent analyst estimates lower.
COAST 1 (N=601, Q4W and Q12W dosing) met all primary and key secondary endpoints at Week 24 across both dosing arms. SHORE (combination with topical corticosteroids) met all EU co-primary endpoints. However, COAST 2 met U.S. co-primary endpoints but narrowly missed EU co-primary endpoints — a differentiated regional outcome that complicates the global regulatory narrative.
Separately, two cases of Kaposi sarcoma were flagged across approximately 4,630 patients exposed in the amlitelimab program; while absolute incidence is low, the FDA typically scrutinizes opportunistic malignancies in immunomodulatory drug development. Leerink cut peak sales estimates by approximately 50% to €650 million for 2032 following the COAST 2 miss.
Sanofi plans regulatory submissions in H2 2026. Amlitelimab's mechanism — selectively blocking OX40L without depleting T cells — is mechanistically distinct from IL-4/IL-13 (dupilumab), IL-13 (tralokinumab), and JAK/TYK2 approaches, potentially carving a niche in patients who do not respond adequately to first-line biologics.
Upstream IP: Amlitelimab (formerly KY1005) was developed at Kymab, which Sanofi acquired in January 2021 for $1.1 billion upfront plus up to $350 million in milestones. Kymab was spun out of the Wellcome Sanger Institute in 2010, but Wellcome's return came through its equity position in Kymab, not through ongoing royalty obligations. No University of Cambridge license was identified — Kymab's IP originated from the Sanger Institute, not the university. No running upstream royalties on amlitelimab net sales were identified in public filings.
Apogee Therapeutics — APEX Phase 2 52-Week Data (Zumilokibart, IL-13 Antibody, Atopic Dermatitis)
Apogee Therapeutics presented 52-week maintenance data from the APEX Phase 2 Part A study of zumilokibart (APG777) at AAD 2026. Zumilokibart is an ultra-long-acting anti-IL-13 antibody with a ~77-day half-life, enabling dosing as infrequently as every three or six months — a potential differentiation from dupilumab's biweekly subcutaneous injections.
Among Week 16 EASI-75 responders continuing into the extension period, 75% of Q3M-dosed patients and 85% of Q6M-dosed patients maintained EASI-75 through 52 weeks. At Week 16, 76.3% achieved clinically meaningful QoL improvement (DLQI 0–1) versus 40.5% for placebo. Phase 3 initiation is planned for H2 2026. If the extended dosing interval is preserved in Phase 3, zumilokibart could represent a meaningful convenience differentiation in the congested atopic dermatitis market — particularly relevant for patients with adherence challenges with biweekly biologics.
Upstream IP: Zumilokibart was licensed from Paragon Therapeutics under a royalty-bearing exclusive worldwide license (April 2023; specific rates redacted). The ultra-long half-life is achieved using YTE Fc engineering technology (MedImmune/AstraZeneca origin), not Xencor's Xtend platform. Paragon is the sole identified upstream royalty obligor.
Connect Biopharma — RADIANT-AD Phase 3 (Rademikibart, IL-4Rα Antibody, Atopic Dermatitis)
Connect Biopharma (also backed by Simcere Pharmaceutical for China rights) reported positive Phase 3 RADIANT-AD results for rademikibart, a monthly subcutaneous anti-IL-4Rα antibody, at AAD 2026. Both U.S. co-primary endpoints were met at Week 16: IGA 0/1 and EASI-75. By Week 52, 87.1% of patients achieved IGA 0/1 and 85.3% achieved EASI-90 — response rates that exceed dupilumab's label rates at comparable timepoints.
Conjunctivitis rates were notably lower than those observed with dupilumab in its pivotal program, which could represent a meaningful tolerability advantage given that dupilumab's conjunctivitis signal (affecting ~10% of patients in pivotal trials) has been a persistent prescriber concern. Connect Biopharma holds ex-China rights; a U.S. regulatory filing timeline was not disclosed. Connect Biopharma raised $20.2 million during the W14 window (covered in Financing Events).
Upstream IP: Rademikibart was developed internally by Connect Biopharma with no disclosed upstream royalty obligations. Connect is the licensor to Simcere for Greater China ($21 million upfront + up to $110 million milestones + tiered royalties up to low double-digit percentages on China net sales). No Regeneron/Sanofi dupilumab patent litigation has been reported.
Additional AAD Presentations
AbbVie — upadacitinib (Rinvoq) in non-segmental vitiligo: Phase 3 data met co-primary repigmentation endpoints through Week 48 in a dedicated vitiligo trial. AbbVie has filed for FDA and EMA approval of this new indication for Rinvoq, which would be the first approved systemic therapy in vitiligo.
Upstream IP: Upadacitinib was internally discovered (ABT-494) with no upstream royalty obligations disclosed. No Abbott legacy IP entanglements.
Pfizer — abrocitinib (Cibinqo) in chronic hand eczema: First Phase 3 results from a dedicated chronic hand eczema trial, meeting co-primary endpoints and supporting a potential label expansion for the JAK1 inhibitor into this underserved indication.
Upstream IP: Entirely internally developed by Pfizer. No upstream royalties or academic licenses of any kind.
Arcutis — roflumilast (ZORYVE) in infants 3–24 months: Phase 2 INTEGUMENT-INFANT study in mild-to-moderate AD showed positive results, supporting a potential pediatric label expansion into the youngest age cohort for the topical PDE4 inhibitor.
Upstream IP: Topical roflumilast was licensed from AstraZeneca in July 2018 for all topical dermatological indications worldwide. Arcutis pays royalties on net sales to AstraZeneca (specific rate redacted in the filed license). Confirmed milestones include $2 million (Phase 2 data) and $10 million upon reaching $250 million cumulative net sales (paid Q1 2025). Arcutis has out-licensed to Huadong Pharmaceutical (Greater China, $30 million upfront + $64.25 million milestones) and Sato Pharmaceutical (Japan, $25 million upfront + $40 million milestones).
Thyroid Eye Disease: Viridian and Immunovant
The thyroid eye disease (TED) competitive landscape saw dramatic developments on both ends of the efficacy spectrum during W14.
Viridian Therapeutics — REVEAL-1 (elegrobart, Phase 3): Viridian reported positive top-line results with proptosis response rates that fell below investor expectations, sending shares down 32-40%. Elegrobart is an anti-FcRn antibody targeting IgG suppression for TED.
Immunovant — GO studies (batoclimab, Phase 3, April 2): Both Phase 3 GO studies of batoclimab in TED missed the primary endpoint of ≥2 mm proptosis response at Week 24. Analysis showed greater improvement during the initial high-dose induction phase, with less durable response during the subsequent lower-dose maintenance period, suggesting that sustained deep IgG suppression may be required for robust proptosis outcomes. Immunovant will not pursue further batoclimab development in TED and is pivoting the program's future entirely to next-generation IMVT-1402, which achieves deeper and more durable IgG reduction. Shares fell approximately 12% in premarket trading April 2.
Upstream IP and Royalty Stack: HanAll Biopharma
Both batoclimab and IMVT-1402 are in-licensed from HanAll Biopharma Co., Ltd. (South Korea) under a 2019 worldwide exclusive collaboration and license agreement. Immunovant owes HanAll up to $442.5 million in remaining development, regulatory, and commercial milestones (net of $32.5 million paid to date), plus tiered royalties from mid-single digits to mid-teens on worldwide net sales — a structure where the royalty rate escalates materially at higher annual revenue thresholds. Roivant Sciences (NASDAQ: ROIV), which owns 64.65% of Immunovant, consolidates these obligations at the parent level.
With batoclimab now confirmed as a non-TED asset, the entire commercial value of the HanAll license rests on IMVT-1402's differentiated FcRn profile across Graves' disease (Phase 3, data expected 2027), myasthenia gravis, and other FcRn-mediated indications. Immunovant held approximately $994 million in cash as of Q3 2025 — sufficient runway through key IMVT-1402 pivotal readouts regardless of the TED setback.
For royalty investors evaluating the HanAll royalty stream on either asset, the estimated 6–15% tiered drag on net sales from the HanAll license represents a meaningful upstream encumbrance that would layer on top of any synthetic royalty financing.
Competitive context: With both batoclimab and elegrobart delivering below-expectation proptosis data in the same week, Horizon Therapeutics (Amgen subsidiary) and its approved teprotumumab (Tepezza) franchise retain significantly stronger competitive positioning than was anticipated entering W14. The TED space is now more bifurcated: established complement and IGF-1R mechanisms (Tepezza) on one side, and a chastened anti-FcRn field on the other. Royalty investors with exposure to Tepezza royalty streams — including legacy Horizon royalty arrangements — may reassess upside scenarios given reduced near-term competitive pressure.
Viridian Therapeutics: Phase 3 REVEAL-1 for Elegrobart in TED (March 30)
Viridian Therapeutics (NASDAQ: VRDN) reported positive Phase 3 results for elegrobart, a half-life-extended anti-IGF-1R antibody delivered via subcutaneous autoinjector, in active thyroid eye disease (TED).
| Parameter | Q4W arm | Q8W arm | Placebo |
|---|---|---|---|
| Proptosis responder rate | 54% | 63% | 18% |
| Complete diplopia resolution | 51% | Not reported | 16% |
| Placebo-adjusted PRR (Q4W) | 36% | --- | --- |
Despite meeting all primary and secondary endpoints, VRDN shares fell approximately 32-40%. The placebo-adjusted PRR of 36% (Q4W) fell below the 50%+ threshold investors expected and trailed cross-trial comparisons to Amgen's Tepezza (51-73% adjusted PRR). The sell-off also reflected elegrobart's underperformance relative to Viridian's own IV formulation, veligrotug, which has a PDUFA date of June 30, 2026. BLA submission for elegrobart is anticipated in Q1 2027.
Upstream IP and Royalty Stack
Elegrobart carries a cumulative estimated 15-22% royalty burden on US sales up to $600 million, one of the highest among deals surveyed this week.
** Both Xencor Xtend Fc license agreements were terminated in 2023 (July 25 and September 7, respectively) with no further financial obligations, per Viridian's SEC filings. The ~4-5% Xencor royalty does not apply to elegrobart.
The surviving layers:
ImmunoGen (now AbbVie, following its March 2024 acquisition) receives mid-single-digit royalties on net sales under a license covering antibodies derived from the EM164 monoclonal antibody. Because elegrobart shares the same binding domain as veligrotug and is an engineered variant, the ImmunoGen license almost certainly extends to elegrobart (~5% estimated). AbbVie is also owed up to $48 million in development milestones and $95 million in commercial milestones.
Enable Injections receives an additional mid-single-digit royalty (~4-5%) for the subcutaneous autoinjector delivery system (January 2023 license, $15 million upfront, up to $195 million milestones), though Viridian's concurrent October 2023 supply agreement with Ypsomed AG for an autoinjector pen device creates uncertainty about which platform will be used commercially.
DRI Healthcare (October 2025, $300 million royalty financing) creates an additional layer: 7.5% on US net sales up to $600 million, stepping down to 0.8% ($600-900 million), 0.25% ($900 million-$2 billion), and 0% above $2 billion.
The ImmunoGen license contains a third-party royalty offset provision that could reduce the total stack, though the offset percentage and floor are both redacted. No freedom-to-operate issues with Amgen/Horizon's Tepezza patents were identified.
Royalty burden estimates on US elegrobart sales (post-Xencor termination):
| US Net Sales Tier | ImmunoGen (AbbVie) | DRI Healthcare | Enable (if used) | Total Est. |
|---|---|---|---|---|
| Up to $600M | ~5% | 7.5% | ~4-5% | ~12.5–17.5% |
| $600M–$900M | ~5% | 0.8% | ~4-5% | ~5.8–10.8% |
| $900M–$2B | ~5% | 0.25% | ~4-5% | ~5.25–10.25% |
| Above $2B | ~5% | 0% | ~4-5% | ~5–10% |
Other Clinical Readouts
CSPC/Alphamab — Anbenitamab (KN026) Phase 3 Positive in HER2+ Breast Cancer (March 31)
CSPC Pharmaceutical Group and Alphamab Oncology reported positive Phase 3 Neo-Healer study results for anbenitamab (KN026), a HER2-targeting bispecific antibody, in the neoadjuvant setting for HER2-positive early breast cancer (March 31). The study met its primary endpoint: statistically significant improvement in total pathological complete response (tpCR) for anbenitamab plus albumin-bound docetaxel versus the standard trastuzumab/pertuzumab/docetaxel (THP) regimen. Anbenitamab simultaneously blocks both HER2 extracellular domain II (pertuzumab epitope) and domain IV (trastuzumab epitope) within a single bispecific construct, replacing the combination of two separate biologics. A regulatory filing is anticipated in China; global development rights outside Greater China remain a watch item for potential out-licensing.
Upstream IP and Royalty Stack: KL Body Platform Clean, Ex-China Rate TBD
Anbenitamab uses Alphamab's proprietary Kappa-Lambda (KL) body bispecific platform, developed internally with no identified third-party platform license. Foundational HER2 antibody patents (trastuzumab, pertuzumab) have largely expired or are expiring, reducing FTO risk. CSPC/Alphamab retains Greater China rights; any ex-China partnership would involve royalties flowing back to CSPC/Alphamab, likely in the mid-to-high single digits based on HER2 bispecific comparables. The clean KL body platform IP makes this asset structurally attractive for any Western company seeking to in-license — the absence of Genmab DuoBody or other bispecific platform royalties means a potential ex-China licensee would face only the CSPC/Alphamab royalty as the primary upstream obligation.
AstraZeneca — EMERALD-3 Phase 3 Positive in Unresectable Hepatocellular Carcinoma (April 2)
AstraZeneca reported positive topline results from the EMERALD-3 Phase 3 trial on April 2, evaluating the combination of Imfinzi (durvalumab) + Imjudo (tremelimumab) + lenvatinib + TACE versus TACE alone in unresectable hepatocellular carcinoma (uHCC). The trial enrolled 760 patients across 171 centers in 22 countries and met its primary progression-free survival endpoint with statistical significance. Interim overall survival showed a favorable directional trend but data remain immature. AstraZeneca announced it is in active discussions with global regulators on the data package.
The result is a meaningful positive for the Imfinzi + Imjudo doublet, which has had a mixed Phase 3 track record. The HIMALAYA trial (uHCC, first-line) supported Imjudo's approval in the same indication; EMERALD-3 extends the combination into an interventional TACE-based backbone, potentially creating a defined role for immune checkpoint doublets in a locoregional-ablative context. Royalty relevance: Imfinzi carries a mid-single-digit royalty to the University of Oxford/MedImmune for underlying PD-L1 antibody IP; Imjudo's tremelimumab was acquired by AstraZeneca from Pfizer (originally CP-675,206) and carries a low-single-digit royalty to legacy Pfizer biologics IP. If EMERALD-3 supports a regulatory submission, incremental uHCC revenues would flow through both royalty layers.
KalVista Pharmaceuticals — KONFIDENT-KID Phase 3 Interim Data in Pediatric HAE (March 30)
KalVista Pharmaceuticals reported positive interim Phase 3 data from the KONFIDENT-KID trial of EKTERLY (sebetralstat) orally dissolving tablet in children aged 2–11 with hereditary angioedema (HAE) on March 30, presented at the Global Angioedema Leadership Conference in Madrid.
Across 172 attacks in 33 pediatric patients, the median time from symptom onset to treatment administration was 25 minutes. Patients treated with the 150mg dose achieved symptomatic relief within approximately 1.5 hours. KONFIDENT-KID is described as the largest interventional pediatric HAE trial ever conducted. KalVista plans to file a U.S. NDA supplemental application for pediatric label expansion in Q3 2026, leveraging the data package alongside the already-approved adult indication. EKTERLY (sebetralstat) was FDA-approved in October 2024 as the first oral on-demand therapy for acute HAE attacks. The pediatric expansion would address an underserved population where current IV or SC on-demand options create significant treatment burden.
Lipocine — LPCN 1154 Phase 3 Fails in Postpartum Depression (April 2)
Lipocine (NASDAQ: LPCN) reported topline Phase 3 results for LPCN 1154 (oral brexanolone) in postpartum depression (PPD) on April 2. The study missed its primary endpoint: in the full analysis set (N=90), LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17 total score versus placebo at the pre-specified 60-hour primary timepoint.
LPCN 1154 is an oral formulation of brexanolone designed for at-home use without medical monitoring — differentiated from Sage/Biogen's approved IV brexanolone (Zulresso), which requires 60-hour inpatient administration. The compound had demonstrated bioequivalence with IV brexanolone in a prior pivotal PK study.
The safety profile was favorable: no treatment-related serious adverse events, no excessive sedation, and no treatment discontinuations — supporting outpatient administration. In a post hoc analysis of patients with a history of psychiatric conditions (n=54), nominally significant HAM-D reductions appeared as early as hour 12 and persisted through day 30. Lipocine has applied for FDA Breakthrough Therapy and Fast Track designations based on these subset signals and will evaluate next steps including potential validation study design, partnerships, and strategic transactions. The company enrolled its last patient in February 2026 and had accumulated $21.5M in cash as of March 2026 following ATM proceeds.
Royalty context: Brexanolone's core neuroactive steroid IP originated at academic institutions and at Sage Therapeutics; Lipocine's LPCN 1154 uses a 505(b)(2) regulatory pathway referencing Zulresso, creating an implicit IP reliance on Sage/Biogen's prior work rather than a direct licensing royalty obligation. No royalty financing relevance at present given the failed primary endpoint.
Priovant / Roivant — Brepocitinib Phase 2b/3 Initiated in Lichen Planopilaris (April 2)
Priovant Therapeutics (a Roivant Sciences subsidiary, NASDAQ: ROIV) announced on April 2 that it has initiated a seamless Phase 2b/3 clinical trial of brepocitinib — its selective dual JAK1/TYK2 inhibitor — in lichen planopilaris (LPP), a rare inflammatory scalp disorder affecting approximately 100,000 adults in the United States that causes irreversible scarring hair loss. First subjects were enrolled in March 2026.
The LPP program becomes the fourth late-stage indication for brepocitinib, alongside ongoing programs in dermatomyositis (Phase 3, with product launch expected September 2026 upon anticipated approval), non-infectious uveitis (Phase 3, topline data expected H2 2026), and cutaneous sarcoidosis (Phase 3 initiation H2 2026). CEO Matt Gline positioned LPP as a "fourth leg to the stool" of a multi-indication rare rheumatology-dermatology franchise with overlapping prescriber bases and thought leaders.
The seamless Phase 2b/3 design (72-patient Phase 2b transitioning directly into ~270-patient Phase 3) allows immediate pivotal enrollment continuity, compressing development timelines. LPP has no FDA-approved treatments; mechanistically, the dual JAK1/TYK2 biology of brepocitinib is well-matched to the inflammatory pathway driving follicular destruction in LPP. Royalty financing relevance is watch-list: if brepocitinib achieves the anticipated DM approval in September 2026, the first commercial cashflows begin and the asset becomes eligible for synthetic royalty financing across its multi-indication franchise.
Regulatory Actions
FDA Approvals
Eli Lilly — Foundayo (Orforglipron) for Obesity (April 1)
On April 1, the FDA granted approval to Foundayo (orforglipron), Eli Lilly's oral small-molecule GLP-1 receptor agonist for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Foundayo is the first oral, non-peptide GLP-1 receptor agonist approved for weight loss, and can be taken at any time of day without food or water restrictions — a meaningful differentiation from semaglutide-based products.
The approval was issued in 50 days under the Commissioner's National Priority Voucher program, making it the fastest novel molecular entity approval since 2002.
Efficacy and Clinical Basis
The approval is supported by the Phase 3 ATTAIN program. ATTAIN-1, the pivotal placebo-controlled study, demonstrated 12.4% mean weight loss (approximately 27 lbs) at 72 weeks on the highest dose (36 mg once daily) versus 0.9% for placebo. Approximately 45% of patients on 36 mg achieved ≥15% body weight reduction. Gastrointestinal adverse events (nausea, vomiting, diarrhea) were the most common, broadly consistent with the GLP-1 class, and were generally transient and dose-dependent.
Pricing and Access
Lilly priced Foundayo at $25/month with commercial insurance and $149–$349/month cash pay (depending on dose), positioning it below injectable competitors on an out-of-pocket basis. LillyDirect shipments began April 6. Lilly disclosed it pre-built $1.5 billion in inventory to support launch supply. The cash-pay price is materially lower than injectable semaglutide products, which has significant implications for commercial formulary positioning and payer negotiations.
Strategic and Royalty Context
The Foundayo approval is directly relevant to the Lilly/Insilico collaboration reported above: Insilico's pipeline page was updated this week to show a GLP-1-targeting candidate out-licensed to an undisclosed partner. Whether Foundayo's approval accelerates or complicates the strategic value of Insilico's GLP-1 program will depend on mechanistic differentiation and target profile.
For royalty investors, Foundayo enters the market without disclosed upstream platform royalties. Orforglipron was discovered using Lilly's internal medicinal chemistry capabilities, with no identified academic co-inventors or platform technology licenses creating royalty stacking risk. This is a notably clean IP position for a blockbuster-trajectory asset.
Vertex — ALYFTREK and TRIKAFTA Label Expansions (April 1)
On April 1, the FDA expanded the labels for both ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) and TRIKAFTA (elexacaftor/tezacaftor/ivacaftor) from variant-specific eligibility to coverage of any CFTR variant known or predicted to produce CFTR protein, regardless of whether clinical data exist for that specific variant.
ALYFTREK now covers patients aged 6 years and older with CF who have at least one variant in a list of 564 responsive mutations. TRIKAFTA now covers patients aged 2 years and older across 521 variants. Approximately 800 additional U.S. CF patients became newly eligible across both labels, bringing total U.S. modulator-eligible CF patients to roughly 95% of the approximately 32,000 people with cystic fibrosis in the United States.
The expansions are supported by mechanistic and in vitro data rather than new clinical trials for each variant, consistent with the FDA's broader biomarker-driven label expansion framework. The decision further entrenches Vertex's near-monopoly position in CF modulator therapy and has no near-term royalty financing implications, given Vertex's fully integrated commercial structure. It is noted here for completeness given the CF modulator market's relevance as a benchmark for royalty-generating rare disease assets.
Biogen: Spinraza High Dose Regimen FDA Approval (March 30)
On March 30, Biogen (NASDAQ: BIIB) announced that the FDA approved a high-dose regimen of Spinraza (nusinersen) for spinal muscular atrophy, comprising a 50 mg loading phase (two doses, 14 days apart) followed by 28 mg maintenance every four months.
| Parameter | Detail |
|---|---|
| Loading dose | 50 mg (two intrathecal injections, 14 days apart) |
| Maintenance dose | 28 mg every 4 months |
| Key trial | DEVOTE study |
| Primary endpoint | +26.19 points CHOP-INTEND improvement vs. sham (p<0.0001) in treatment-naive symptomatic infants |
| WAC pricing | 28 mg vial: ~$152,000; 50 mg vial: ~$271,000 |
| Additional approvals | EU, Switzerland, Japan |
The approval reinvigorates Biogen's SMA franchise against Roche's oral Evrysdi and Novartis' gene therapy Zolgensma/Itvisma. Ionis Pharmaceuticals receives royalties in the low-to-mid teens percentage on net Spinraza sales as the originating licensor, making this approval directly relevant to Ionis's royalty revenue and to any holders of Spinraza-linked royalty instruments.
The full royalty cascade on Spinraza runs through multiple parties. Biogen pays Ionis tiered royalties up to the mid-teens (~11-15% estimated) under the August 2016 exclusive license, with Ionis earning more than $1.8 billion in cumulative royalties through September 2024. Within Ionis's royalty income, sub-royalties flow to Cold Spring Harbor Laboratory (Adrian Krainer, co-inventor) and the University of Massachusetts Medical School at undisclosed rates (estimated 1-5% and 1-3% respectively).
In January 2023, Ionis sold a portion of these royalties to Royalty Pharma for $500 million upfront plus up to $625 million in milestones: RPRX receives 25% of Ionis's Spinraza royalties through 2027, increasing to 45% in 2028. The high-dose formulation (same nusinersen molecule, higher concentration) falls under the existing agreement with no additional IP obligations.
Teva: PONLIMSI (Denosumab Biosimilar) FDA Approval (March 30)
On March 30, Teva (NYSE: TEVA) received FDA approval for PONLIMSI (denosumab-adet), a biosimilar to Amgen's Prolia (denosumab), across all reference product indications: postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis, and bone loss from hormone ablation in cancer.
Prolia generated over $3 billion in global sales in 2025. No interchangeability designation was specified. Launch timing and WAC pricing have not been disclosed. Teva simultaneously secured FDA and EMA acceptance of applications for a proposed Xolair (omalizumab) biosimilar, extending its biosimilar portfolio.
The most notable finding on PONLIMSI is what is absent: no publicly disclosed BPCIA litigation between Amgen and Teva, despite Amgen having sued at least 11 other denosumab biosimilar applicants (Sandoz, Celltrion, Samsung Bioepis, Fresenius Kabi, Accord/Intas, Hikma, Biocon, Henlius/Organon, Dr. Reddy's/Alvotech, Amneal, and Alkem). All existing settlements contain confidential financial terms with staggered launch dates. Amgen's core composition patent expired February 2025, but secondary manufacturing patents extend into the 2030s. Teva's absence from public dockets suggests either a pre-suit confidential settlement or a royalty-free arrangement. Halozyme ENHANZE technology is not involved (standard SC injection).
NDA/BLA Submissions and Acceptances
Cogent Biosciences — Bezuclastinib NDA Submitted Under RTOR (April 1)
Cogent Biosciences announced the submission of a New Drug Application for bezuclastinib for second-line gastrointestinal stromal tumors (GIST) in combination with sunitinib, under the FDA's Real-Time Oncology Review (RTOR) program. The submission is based on positive Phase 3 PEAK trial data. Bezuclastinib received Breakthrough Therapy Designation in January 2026 and is a selective KIT D816V inhibitor designed to overcome the resistance mutations that limit second-line sunitinib benefit.
Upstream IP and Royalty Stack: Plexxikon/Daiichi Sankyo License Confirmed
Bezuclastinib (originally PLX9486) was licensed from Plexxikon Inc., a wholly owned subsidiary of Daiichi Sankyo. Cogent's 10-K filings disclose mid-to-high single-digit royalty payments to Plexxikon on net sales, plus development and regulatory milestones.
Cogent's founders include former Blueprint Medicines scientists, but no Blueprint IP is involved — the overlap with Blueprint is competitive (both target KIT D816V via selective inhibitors), not IP-related. No academic upstream obligations were identified.
For royalty investors, bezuclastinib's royalty stack is lighter than many oncology assets but is not zero — the Plexxikon/Daiichi Sankyo layer (~5–8% estimated) would sit beneath any synthetic royalty financing.
Scholar Rock — Apitegromab BLA Resubmitted for SMA (March 31)
Scholar Rock resubmitted its Biologics License Application for apitegromab in spinal muscular atrophy (SMA). The resubmission addresses the FDA's prior Complete Response Letter, which cited manufacturing concerns; Scholar Rock added a second U.S. fill-finish facility alongside the Catalent/Novo Nordisk Bloomington site to resolve the agency's CMC concerns. FDA acceptance of the resubmission is expected within 30 days, with a new PDUFA date likely set for late September 2026.
Upstream IP: Scholar Rock holds an exclusive worldwide license from Children's Medical Center Corporation (Boston Children's Hospital), effective December 2013, covering co-owned platform patents. The license includes maintenance fees and retains CMCC rights for research. Co-founders Timothy Springer and Leonard Zon are Harvard Medical School faculty, but IP flows through Boston Children's Hospital. Commercial royalty terms are not fully disclosed but represent a confirmed upstream obligation.
Separately, Biogen executed a $250 million Royalty Pharma R&D co-funding deal for apitegromab in February 2025, creating a mid-single-digit RPRX royalty layer on worldwide sales if approved.
Praxis Precision Medicine: Relutrigine NDA Accepted with Priority Review (March 30)
Praxis Precision Medicine (NASDAQ: PRAX) announced on March 30 that the FDA accepted the NDA for relutrigine, a first-in-class sodium channel modulator for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs), and granted Priority Review with a PDUFA target date of September 27, 2026. Relutrigine holds Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations and would be the first FDA-approved therapy for these severe pediatric epilepsies. Approval would trigger a Rare Pediatric Disease PRV worth an estimated $150-160 million based on recent transactions.
Orca Bio — Orca-T PDUFA Date Extended (April 1)
The FDA extended the review period for Orca-T, Orca Bio's allogeneic stem cell and T-cell immunotherapy for AML, ALL, and MDS, by three months to accommodate updated chemistry, manufacturing, and controls (CMC) information. The original PDUFA date was April 6, 2026.
FDA Designations
Caribou Biosciences: CB-011 RMAT Designation (March 31)
Caribou Biosciences (NASDAQ: CRBU) received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for CB-011, its allogeneic anti-BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma. CB-011 already held Fast Track and Orphan Drug designations. The RMAT designation is notable given the competitive dynamics in the allogeneic CAR-T space, where Gilead's Arcellx acquisition (autologous BCMA CAR-T, W13) and BMS/2Seventy Bio's Abecma franchise represent the dominant autologous competitors.
Cocrystal Pharma — CDI-988 Fast Track for Norovirus (April 2)
Cocrystal Pharma received FDA Fast Track Designation for CDI-988, a 3CL protease inhibitor in Phase 1b human challenge studies at Emory University, for the treatment and prevention of norovirus infection. CDI-988 is the first oral antiviral candidate for norovirus to receive this designation.
Context Therapeutics — CTIM-76 Fast Track for Ovarian Cancer (April 2)
Context Therapeutics received FDA Fast Track Designation for CTIM-76, a CLDN6 × CD3 bispecific antibody in Phase 1 dose escalation, for platinum-resistant ovarian cancer. Interim Phase 1 data are expected June 2026.
EMA Actions
Savara: EMA Validates MOLBREEVI MAA for Autoimmune PAP (March 30)
Savara (NASDAQ: SVRA) announced on March 30 that the EMA has validated the Marketing Authorization Application for MOLBREEVI (molgramostim inhalation solution) in autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The CHMP review has commenced. In the U.S., the FDA is reviewing the MOLBREEVI BLA under Priority Review with an August 22, 2026 PDUFA date. The MHRA submission was also completed in March 2026. If approved, MOLBREEVI would be the first and only approved therapy for autoimmune PAP in both the U.S. and Europe.
EMA CHMP March Plenary: Positive Opinions (Published March 27, Effective W14)
The EMA's Committee for Medicinal Products for Human Use issued a cluster of positive opinions at its March 23–26 plenary that became publicly effective during the W14 window. The most commercially significant:
Imdylltra (tarlatamab, Amgen): Positive CHMP opinion for relapsed or refractory extensive-stage small cell lung cancer after at least two prior therapies. Amgen received FDA approval for Imdylltra in the U.S. in May 2024; EU approval would unlock a market with approximately 40,000 new ES-SCLC diagnoses annually.
Adstiladrin (nadofaragene firadenovec, Ferring): Conditional marketing authorization recommended for BCG-unresponsive non-muscle-invasive bladder cancer. Already FDA-approved in the U.S. since December 2022.
Zepzelca (lurbinectedin, PharmaMar): Positive opinion for extensive-stage SCLC maintenance therapy. PharmaMar holds EU rights; Jazz Pharmaceuticals holds U.S. rights and collects royalties on European sales under its licensing arrangement.
Sarclisa (isatuximab) subcutaneous formulation (Sanofi): Positive opinion for label expansion to include a subcutaneous administration option in multiple myeloma, potentially improving patient convenience and expanding market share versus IV formulations.
HYMPAVZI (marstacimab, Pfizer): Positive opinion expanding the label to cover hemophilia A and B patients with inhibitors, a higher-need population than the existing without-inhibitor indication.
Joenja (leniolisib, Pharming): Positive opinion under exceptional circumstances for activated PI3K delta syndrome (APDS), a rare primary immunodeficiency.
The CHMP also adopted a reflection paper on tailored biosimilar development, opening the door to potential waivers of certain clinical data requirements for biosimilars with extensive comparability evidence — a development with long-term implications for biosimilar royalty economics.
Notable negatives from the same plenary: the Anavex application for blarcamesine in Alzheimer's disease was withdrawn following a negative trend in the CHMP review, and the Hetlioz (tasimelteon) application for Smith-Magenis syndrome received a confirmed refusal.
Safety Communications
Amgen / FDA — Tavneos (Avacopan) Drug Safety Communication (March 31)
The FDA issued a Drug Safety Communication on March 31 detailing drug-induced liver injury (DILI) findings for Tavneos (avacopan), Amgen's C5a receptor inhibitor approved for ANCA-associated vasculitis. The communication identified 76 cases worldwide with reasonable evidence of causal association, including 54 hospitalizations, 8 deaths, and 7 cases of vanishing bile duct syndrome (3 fatal) — a particularly severe and often irreversible cholestatic injury pattern.
FDA had requested Amgen voluntarily withdraw Tavneos in January 2026; Amgen formally refused on January 28, citing its view that the benefit-risk profile remains acceptable with enhanced monitoring. Tavneos remains on market while the parties engage on a regulatory path forward.
The communication adds a boxed warning-level severity signal to an already commercially challenged product (approximately $150 million in 2025 revenues against high clinical monitoring requirements). Royalty investors tracking avacopan-based royalty streams should note that a potential future withdrawal or REMS with restricted access would materially impair royalty economics.
AACR Annual Meeting 2026: Regular Abstracts Published (April 3)
The American Association for Cancer Research (AACR) published Part 1 of the Annual Meeting 2026 regular abstracts on April 3 as an online supplement to Cancer Research, making thousands of oncology research findings publicly available in advance of the meeting (San Diego, April 17–22, 2026). Clinical trial and late-breaking abstracts (Part 2) remain embargoed until April 17. The abstract publication is a standard annual event, but its timing at the close of W14 initiates an approximately two-week period of oncology data previewing that will drive material newsflow in W15 and W16, with implications for deal-making, financing rounds, and royalty asset valuations across the oncology pipeline.
Financing Events
Blackstone Life Sciences VI: Record $6.3 Billion Fund Close (March 30)
Blackstone (NYSE: BX) announced on March 30 the final close of Blackstone Life Sciences VI (BXLS VI) at its hard cap of $6.3 billion in total capital commitments, making it the largest private fund ever dedicated solely to life sciences and nearly 40% larger than its predecessor BXLS V ($4.6 billion, closed 2020).
| Term | Detail |
|---|---|
| Fund | Blackstone Life Sciences VI (BXLS VI) |
| Size | $6.3 billion (hard cap, oversubscribed) |
| Predecessor | BXLS V ($4.6 billion, 2020) |
| Growth | ~37% increase |
| Total BXLS AUM | $15 billion |
| Capital deployed (last 12 months) | Nearly $2 billion |
| Track record | 34 regulatory approvals; 86% Phase III success rate |
| Leadership | Nicholas Galakatos, Ph.D., Global Head of BXLS |
| Strategy | Full lifecycle investing across biopharma and medtech, including royalty transactions |
BXLS has established itself as a leading seller of drug and medical technology royalties by transaction count, making it a direct participant in the royalty financing ecosystem. Notable portfolio investments include Alnylam ($2 billion strategic financing), Teva ($400 million growth capital for duvakitug), and Anthos Therapeutics (acquired by Novartis for up to $3.1 billion).
BXLS functions as the pharmaceutical industry's premier synthetic royalty creator: it originates royalty interests by funding late-stage development, then frequently sells those interests to aggregators. Recent examples include selling the Alnylam/AMVUTTRA 1% royalty (acquired for $70 million) to Royalty Pharma for $310 million in November 2025, and the $700 million Merck/sacituzumab tirumotecan deal for low-to-mid single-digit royalties. Per ZS Associates data, Blackstone is the third-largest royalty originator by transaction value (2012-2022), behind Royalty Pharma and Healthcare Royalty Partners. The BXLS-RPRX relationship is symbiotic: BXLS creates, RPRX aggregates.
Kailera Therapeutics: S-1 Filing for Nasdaq IPO (Filed March 27; IPO Process Active During W14)
Kailera Therapeutics filed its S-1 registration statement seeking to list on Nasdaq under the ticker KLRA, with a placeholder raise of $100 million. The obesity-focused biotech has raised over $1 billion privately, is backed primarily by Bain Capital (~46% equity), and ended 2025 with $652.7 million in cash.
| Term | Detail |
|---|---|
| Lead asset | Ribupatide (KAI-9531), once-weekly injectable GLP-1/GIP dual agonist |
| Stage | Global Phase 3 program (KaiNETIC) |
| Key data | Phase 3 China: 18% average body weight loss at 48 weeks |
| Oral formulation | Phase 2: up to 12.1% weight loss at 26 weeks |
| Pipeline | Oral small-molecule GLP-1 agonist; tri-agonist (GLP-1/GIP/glucagon) |
| License source | Jiangsu Hengrui ($100M upfront + $10M technology transfer) |
| Underwriters | JPMorgan, Jefferies, Leerink Partners, TD Cowen, Evercore ISI, William Blair |
The S-1 discloses the full Hengrui license architecture. Total potential payments across all four licensed assets reach approximately $6.035 billion: $110 million already paid, up to $200 million in development/regulatory milestones, and up to $5.725 billion in sales milestones. Tiered royalties on ex-Greater China net sales are disclosed in aggregate terms with specific rates redacted; based on comparable Hengrui out-license structures and the S-1's aggregate description of "low-single-digit to low-double-digit percentages," the estimated per-asset ranges are:
- HRS-7535 / ribupatide (Phase 3, injectable GLP-1/GIP): ~3–8% tiered
- HRS-9531 (Phase 2, oral GLP-1/GIP): ~3–8% tiered
- HRS-1780 (Phase 1, GLP-1/GCGR dual agonist): ~2–6% tiered
- HRS-1893 (preclinical, amylin analog): ~2–5% tiered
Note on HRS-1893: The Kailera S-1 lists HRS-1893 as a preclinical amylin analog in its licensed portfolio. However, Hengrui separately licensed HRS-1893 as a cardiac myosin inhibitor (not an amylin analog) to Braveheart Bio in September 2025 under a distinct exclusive license covering all territories outside Greater China/Taiwan.
Braveheart Bio launched with a $185 million Series A and presented positive Phase 2 oHCM data at ACC.26 on March 30 (see ACC.26 section above).
Whether the Kailera S-1 reference to "HRS-1893" denotes the same compound in a metabolic indication or a distinct molecule sharing the same internal code requires clarification from the Kailera S-1 amendment or prospectus supplement. Kailera's licensed assets are focused exclusively on obesity/metabolic disease; the oHCM indication is covered under Braveheart's license.
Sublicense obligation: If Kailera sub-licenses any asset regionally, it owes Hengrui a mid-teens to low-twenties percentage of sublicense revenue received — a significant obligation that would route a material portion of any partnering upfront payments back to Hengrui before they reach Kailera shareholders.
Hengrui's 13.6% pre-IPO equity stake provides additional economic participation beyond the royalty and sublicense streams. All four candidates were originated by Hengrui with no identified upstream third-party IP encumbrances, though freedom-to-operate in the densely patented GLP-1 landscape (Novo Nordisk, Eli Lilly) remains a competitive consideration.
Royalty Financings
Athyrium Capital Management / Esperion Therapeutics: $50 Million Japan Royalty Financing (April 2)
On April 2, Athyrium Capital Management and Esperion Therapeutics (NASDAQ: ESPR) announced a $50 million royalty purchase agreement under which funds managed by Athyrium will acquire 100% of Esperion's royalty interest in Otsuka Pharmaceutical's net sales of bempedoic acid products in Japan from January 1, 2026 forward, together with associated regulatory and commercial milestone payments, subject to a cap. Simultaneously, Esperion executed a First Amendment to its existing Credit Agreement adding $25 million in incremental term loans with reset call protection. Together the two transactions provide $75 million in new capital to fund Esperion's concurrent acquisition of Corstasis Therapeutics and its approved cardiovascular product Enbumyst (bumetanide nasal spray).
Deal Structure
| Term | Detail |
|---|---|
| Royalty purchaser | Athyrium Opportunities IV Acquisition (funds managed by Athyrium Capital Management) |
| Seller | Esperion Therapeutics, Inc. (NASDAQ: ESPR) |
| Asset monetized | 100% of Esperion's royalty interest in Otsuka's Japan net sales of bempedoic acid products (Nilemdo/Nustendi), from January 1, 2026 |
| Purchase price | $50 million |
| Royalty rates | Tiered: 12% to 33% of Japan net sales |
| Cap / reversion | Athyrium receives payments until aggregate collections reach 2.0x invested capital ($100 million); 100% of future Japan royalties and milestones then revert to Esperion |
| Signed / effective | April 2, 2026 |
| Concurrent debt | $25 million incremental term loans via First Amendment to Credit Agreement; administrative agent GLAS USA / GLAS Americas; make-whole plus 3% call protection through year two, step-down thereafter |
| Use of proceeds | Fund acquisition of Corstasis Therapeutics (Enbumyst) and general corporate purposes |
| Financial advisor (Esperion) | Jefferies LLC |
| Legal advisor (Esperion) | Gibson, Dunn & Crutcher LLP |
| Legal advisor (Athyrium) | Covington & Burling LLP and Paul Hastings LLP |
Context
This is Athyrium's second financing with Esperion in 16 months, following Athyrium's participation in Esperion's $150 million senior secured loan facility that closed in December 2024. The repeat investment reflects Athyrium's continued conviction in the bempedoic acid franchise and illustrates the increasingly common structure of royalty financings layered on top of existing debt relationships — a pattern that allows specialist royalty investors to deepen exposure to a commercial asset through multiple instruments across a company's capital stack.
HealthCare Royalty clarification: The March 3, 2026 Esperion/Corstasis announcement referenced the Japan royalty monetization being funded by "Athyrium Capital Management and HealthCare Royalty," creating market confusion.
The April 2 SEC 8-K (Accession No. 000162828026023196) resolves this definitively: the $50 million Royalty Purchase Agreement was executed solely by Athyrium Opportunities IV Acquisition LP — HealthCare Royalty is not a counterparty to the royalty transaction.
HealthCare Royalty's role is limited to co-lending in the existing $150 million senior secured term loan (December 2024) and the concurrent $25 million incremental term loan. The credit facility carries 9.75% cash or 11.75% PIK interest, with interest-only payments for four years, quarterly 12.50% amortization thereafter, and a five-year maturity.
Call protection resets from April 2: make-whole plus 3% through year 2, then 3% (year 3), 1% (year 4), par thereafter. Administrative agent: GLAS USA LLC / GLAS Americas LLC.
Bempedoic acid in Japan is marketed by Otsuka under the brand names Nilemdo (bempedoic acid monotherapy) and Nustendi (bempedoic acid/ezetimibe combination) pursuant to the April 2020 License and Collaboration Agreement with Esperion. Japan's LDL-C management market is large and growing, driven by aging demographics and increasing cardiovascular risk awareness, though bempedoic acid's Japan penetration remains in early commercial stages — making the 12–33% tiered royalty rate and the 2.0x cap structure a reflection of both the asset's upside optionality and the investor's need for downside protection in a nascent market.
Corstasis Therapeutics (the acquisition being funded) is a commercial-stage cardiovascular company whose lead product, Enbumyst (bumetanide nasal spray), is the first and only FDA-approved intranasal loop diuretic for edema associated with cardiovascular, hepatic, and renal disease. The acquisition adds a second commercial product to Esperion's portfolio alongside its bempedoic acid franchise, creating a broader cardiometabolic commercial infrastructure.
Royalty Stack Analysis
| Layer | Obligor | Rate / Terms |
|---|---|---|
| Athyrium Japan royalty purchase | Esperion (via Otsuka Japan sales) | 12–33% tiered; 2.0x cap, then full reversion |
| Otsuka license royalty (to Esperion) | Otsuka Pharmaceutical | Undisclosed; governed by April 2020 License Agreement |
| Upstream academic IP (bempedoic acid / ACL inhibition) | Esperion (originator) | Bempedoic acid was discovered internally at Esperion; no identified third-party academic royalty encumbering the compound |
The IP position is notably clean: bempedoic acid was discovered by Esperion's internal research team building on the company's proprietary ACLY (ATP citrate lyase) biology platform, with no identified upstream academic license generating a royalty obligation on the compound. The sole royalty layer above Athyrium is the Otsuka-to-Esperion Japan license payment, which Athyrium has now purchased in full until the 2.0x cap is reached. For royalty investors, the absence of upstream IP stacking and the defined reversion trigger make this a structurally clean instrument — though exposure is concentrated in a single geography (Japan) and a single licensee (Otsuka) with limited secondary market liquidity.
Fortress Biotech / Cyprium: $205 Million Priority Review Voucher Sale (March 30)
On March 30, Fortress Biotech (NASDAQ: FBIO) announced that its subsidiary Cyprium Therapeutics had completed the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million. The PRV was generated by Cyprium's FDA approval of ZYCUBO (copper histidinate injection) for Menkes disease, one of the rarest pediatric genetic disorders.
Deal Structure
| Term | Detail |
|---|---|
| Seller | Cyprium Therapeutics (Fortress Biotech subsidiary) |
| Asset sold | Rare Pediatric Disease Priority Review Voucher |
| Gross proceeds | $205 million |
| Buyer | Undisclosed |
| Retained economics | Fortress/Cyprium retain tiered royalties and sales milestones on ZYCUBO via the commercial partner Sentynl Therapeutics |
Context
PRV sales have become a significant alternative capital source for rare disease developers, with voucher values ranging from $100 million to over $300 million in recent transactions. The $205 million price is in line with the high end of 2024-2025 PRV transactions and reflects continued strong demand from large pharmaceutical companies seeking to accelerate FDA review timelines for priority assets.
Cyprium retains commercial upside on ZYCUBO itself through its Sentynl Therapeutics partnership: tiered royalties on net sales and sales-based milestones mean the PRV sale is a pure capital event that does not extinguish the underlying commercial economics. Menkes disease affects approximately 1 in 100,000 live births and has no other approved treatments; the ZYCUBO addressable population is small but the orphan economics (7-year market exclusivity, Orphan Drug Tax Credit) and pricing flexibility are significant.
Royalty financing relevance: moderate. The structure — PRV monetised upfront, royalties and milestones retained through a commercial partner — is a textbook hybrid of regulatory asset monetisation plus ongoing royalty participation. The Sentynl royalty stream on ZYCUBO could become a royalty financing candidate if Sentynl or Fortress seeks non-dilutive capital against that cashflow. The $205 million PRV proceeds provide immediate liquidity to Fortress, which has historically used subsidiary proceeds to fund its broader portfolio pipeline.
Upstream IP and Royalty Stack: NIH License Is the Critical Layer
ZYCUBO's scientific origins trace to NIH — specifically to research by Dr. Stephen Kaler at the NIH National Institute of Child Health and Human Development (NICHD), who demonstrated in the 1990s and 2000s that copper histidinate could cross the blood-brain barrier and address the neurological deficits of Menkes disease. NIH filed patents on this therapeutic application of copper histidinate; Cyprium holds an exclusive license from NIH on the Kaler copper histidinate IP, confirmed in Fortress's 10-K filings though specific royalty rates are redacted. NIH standard exclusive licenses for this type of early-stage therapeutic IP carry royalties estimated at 2–5% on net sales plus milestone payments to NIH.
The commercial flows then layer as follows:
| Layer | Direction | Party | Est. Rate |
|---|---|---|---|
| NIH / Kaler IP | Outflow | U.S. Government (NIH) | ~2–5% on net sales |
| Sentynl commercial agreement | Inflow | Cyprium/Fortress | ~mid-to-high single digits to low-teens (est. 6–15%) |
| Net royalty position | Positive | Fortress/Cyprium | ~1–13% net inflow |
The Menkes disease patient population is extremely small (~3,000 U.S. patients, with only a subset receiving treatment), so absolute royalty dollar flows will be modest regardless of rate. The commercial value lies primarily in orphan drug pricing power (ZYCUBO's list price is several hundred thousand dollars annually), market exclusivity through 2033, and the Orphan Drug Tax Credit that incentivizes the program. The PRV sale converts future regulatory optionality into immediate liquidity while preserving the ongoing royalty economics.
Additional Priority Review Voucher Issuances (April 1–2)
Two additional Rare Pediatric Disease Priority Review Vouchers were formally issued via Federal Register notices during the W14 window, adding new tradeable assets to the PRV market:
Ascendis Pharma — YUVIWEL (navepegritide) PRV: The FDA published notice on April 1 of a PRV issued to Ascendis Pharma for YUVIWEL, approved February 27, 2026 for achondroplasia. YUVIWEL is a long-acting C-type natriuretic peptide (CNP) analog using Ascendis's TransCon platform.
Rocket Pharmaceuticals — KRESLADI (marnetegragene autotemcel) PRV: The FDA published notice on April 2 of a PRV issued to Rocket Pharmaceuticals for KRESLADI, approved March 26, 2026 for severe leukocyte adhesion deficiency-I (LAD-I), an ultra-rare primary immunodeficiency affecting approximately 1 in 100,000 live births. KRESLADI is a lentiviral-based ex vivo gene therapy.
Neither company has announced a sale of their respective PRV. Based on recent transaction prices (Fortress/Cyprium $205 million above; prior 2025 transactions ranging from $100–300 million), each voucher represents an estimated $100–200 million in potential monetisation value. Royalty investors tracking the PRV secondary market should note the increased supply: three PRVs entered the tradeable pool during W14 alone (Cyprium sale, Ascendis issuance, Rocket issuance), which may exert modest downward pressure on clearing prices if multiple sellers approach the market simultaneously.
Debt and Structured Credit
Zenas BioPharma / BioPharma Credit (Pharmakon): $250 Million Senior Secured Term Loan (March 2026)
Zenas BioPharma (NASDAQ: ZBIO) closed a $250 million senior secured term loan facility from funds managed by Pharmakon Advisors (BioPharma Credit PLC, BPCR Limited Partnership, and BioPharma Credit Investments V (Master) LP), with Tranche A funding completed in late March 2026 and the Akin Gump advisory press release confirming the structure on April 2.
| Term | Detail |
|---|---|
| Borrower | Zenas BioPharma (NASDAQ: ZBIO) |
| Lenders | BioPharma Credit PLC / BPCR Limited Partnership / BioPharma Credit Investments V (all managed by Pharmakon Advisors) |
| Total facility | $250 million across five tranches |
| Tranche A | $75 million (funded at closing, late March 2026) |
| Tranches B–E | Up to $175 million available through April 30, 2029 |
| Discretionary tranches | $125 million at Zenas's option |
| Milestone-linked tranches | Remainder tied to obexelimab regulatory and commercial milestones |
| Maturity | March 27, 2031 (5-year term) |
| Interest rate | Mid-single-digit spread over SOFR |
| Legal advisor (Pharmakon) | Akin Gump Strauss Hauer & Feld LLP |
The primary asset underpinning the facility is obexelimab, an anti-CD19 antibody approaching BLA filing for IgG4-related disease (IgG4-RD). Zenas separately holds a $300 million synthetic royalty agreement with Royalty Pharma (signed September 2025) on obexelimab — creating a layered capital structure where secured Pharmakon debt sits alongside an existing RPRX royalty monetization on the same commercial asset. This dual-instrument structure illustrates how pre-commercial biotechs are increasingly deploying royalty monetization and specialty pharma credit in sequence, maximising non-dilutive capital while the primary asset approaches BLA filing. For royalty investors, the stacked structure means obexelimab's future net sales must simultaneously service Pharmakon debt and the RPRX royalty — a coverage ratio dynamic requiring careful underwriting before any additional royalty transactions are layered on this asset.
Concurrent Zenas Capital Markets Transactions (March 26–31)
In addition to the Pharmakon term loan, Zenas executed two concurrent public capital markets transactions during the W14 window, raising approximately $294 million in aggregate:
$200 million 2.50% Convertible Senior Notes due 2032: Priced March 26 and closed March 31, with Jefferies, Evercore, Citigroup, and Guggenheim Securities as joint bookrunners. The notes carry a 2.50% coupon, paid semi-annually, and are general unsecured senior obligations. An additional $30 million greenshoe option was granted to underwriters (exercisable within 30 days).
~$93.7 million follow-on equity offering: Concurrent public stock offering, also closing March 31.
The three instruments together — $250 million Pharmakon term loan, $200 million convertible notes, and ~$93.7 million equity offering — represent approximately $544 million in new capital raised across one week, an extraordinary capital structure build-out for a pre-approval biotech. Combined with the pre-existing $300 million Royalty Pharma synthetic royalty, obexelimab now underpins more than $840 million in committed or deployed external capital before BLA filing. This multi-layered structure — secured debt (Pharmakon), unsecured convertible debt, equity, and royalty monetization (RPRX) — is among the most complex pre-commercial capital stacks in biotech and warrants close monitoring by royalty investors evaluating additional synthetic royalty exposure on the asset.
Venture and Private Placements
Ambrosia Biosciences: $100 Million Series B (March 31)
On March 31, Ambrosia Biosciences announced a $100 million oversubscribed Series B financing to advance its novel small-molecule, non-peptide GLP-1 receptor agonist pipeline for obesity and cardiometabolic disease.
| Term | Detail |
|---|---|
| Company | Ambrosia Biosciences (private, Boulder, CO) |
| Round | Series B — $100 million (oversubscribed) |
| Lead investors (new) | Blue Owl Healthcare Opportunities, Redmile Group, Deep Track Capital |
| Participating (existing) | BVF Partners, Boulder Ventures |
| New institutional | Janus Henderson, Samsara BioCapital |
| Lead program | Oral small-molecule (non-peptide) GLP-1 receptor agonist — Phase 1 initiation planned 2026 |
| Prior raise | $16 million Series A, mid-2024 |
The Foundayo approval the same week creates an interesting context: Ambrosia's thesis is that next-generation oral GLP-1s with differentiated pharmacology (selectivity profiles, dosing flexibility, tolerability) will compete with orforglipron even in a post-Foundayo market. Blue Owl Healthcare Opportunities' participation is notable given the firm's established pharma royalty investment track record; whether this financing includes any royalty or synthetic royalty component was not disclosed.
Syneron Bio: $150 Million Series B (Closed March 31)
Syneron Bio (Beijing), a macrocyclic peptide drug discovery company, closed a $150 million Series B on March 31, 2026. The round was co-led by an unnamed international life sciences fund, Decheng Capital, and CDH VGC, with participation from an Abu Dhabi Investment Authority (ADIA) subsidiary, True Light Capital (Temasek subsidiary), Qiming Venture Partners, BioTrack Capital, and existing shareholders including AstraZeneca, LAV, Sinovation Capital, 5Y Capital, GL Ventures, Biotech Development Fund, and Lenovo Capital.
| Term | Detail |
|---|---|
| Company | Syneron Bio (private, Beijing) |
| Round | Series B — $150 million |
| Co-leads | International life sciences fund (unnamed), Decheng Capital, CDH VGC |
| Notable new investors | ADIA subsidiary, True Light Capital (Temasek), Qiming Venture Partners, BioTrack Capital |
| Platform | Synova™ macrocyclic peptide discovery platform |
| Pipeline | Diversified: oncology, autoimmune, metabolic, and rare diseases |
| Use of proceeds | Platform advancement and pipeline IND filings |
Syneron's proprietary Synova™ platform enables de novo discovery of macrocyclic peptides — a molecular class positioned between small molecules and biologics, combining oral bioavailability with antibody-like target selectivity. The company previously signed a $3.4 billion biobucks collaboration with AstraZeneca in March 2025, making it one of the most heavily partnered China-based peptide discovery platforms. The sovereign wealth fund participation (ADIA, Temasek) signals institutional conviction in macrocyclic peptides as a validated drug modality alongside the oral GLP-1 and ADC platforms that dominated 2025-2026 licensing activity.
Royalty financing relevance: watch list. Syneron's assets are preclinical, but the AstraZeneca collaboration economics — if any programs advance to Phase 2 — could generate royalty streams amenable to monetization. The $150 million raise, combined with the $3.4 billion AstraZeneca partnership, positions Syneron among the best-capitalised private peptide companies globally.
Centivax: $37 Million Oversubscribed Financing (March 30)
Centivax (South San Francisco) closed a $37 million oversubscribed financing led by Structure Fund (co-led by Oliver Mulherin and Sam Altman), with participation from Meiji Seika Pharma, Sigmas Group, Kendall Capital Partners, and Stripe co-founders Patrick and John Collison. The company has now raised $133 million to date following a $45 million Series A in July 2025. Centivax is developing Centi-Flu, a universal flu vaccine currently in Phase 1 (data expected end of 2026), with Phase 2 targeted for early 2027. The financing supports Phase 2 clinical material, GMP manufacturing scale-up, and advancement of follow-on universal immunity programs.
Centivax owns its core IP outright: USPTO patent records show the epitope focusing patent family (US 9,884,893; US 10,196,427; US 10,836,797) was fully assigned (not licensed) from Charles River Laboratories in March 2021, following Charles River's $83 million acquisition of Distributed Bio. No ongoing royalty to Charles River exists. However, Centivax has received over $26 million in non-dilutive government funding (NIH, CEPI, Gates Foundation, DARPA), triggering Bayh-Dole Act march-in rights and CEPI equitable access commitments.
Connect Biopharma: $20.2 Million Private Placement (March 30)
Connect Biopharma (NASDAQ: CNTB) announced a $20.2 million private placement, selling 6.13 million ordinary shares at $3.25/share to institutional investors. The round was led by Panacea Venture (Connect's largest existing investor). Leerink Partners and Cantor Fitzgerald served as joint placement agents. Proceeds extend cash runway into H2 2027 for development of rademikibart, a next-generation anti-IL-4Ralpha antibody for acute exacerbations of asthma and COPD. Connect has an existing license deal with Simcere for Greater China (up to ~$110 million in milestones).
The placement was timed alongside significant clinical catalysts: Simcere presented Phase 3 RADIANT-AD 52-week data for rademikibart at AAD 2026 showing EASI-75 of 96.6% and IGA 0/1 of 87.1% in atopic dermatitis, potentially best-in-class results. Connect separately reported positive Phase 1 IV rademikibart data in asthma/COPD on March 30.
Aprea Therapeutics: $30 Million Private Placement (March 30)
Aprea Therapeutics (NASDAQ: APRE) announced an oversubscribed $30 million private placement led by Soleus Capital, with participation from Vestal Point Capital, Squadron Capital Management, and other investors. The company is selling pre-funded warrants to purchase up to 37.2 million shares at $0.807 and accompanying warrants exercisable at $0.683/share. Aprea is developing APR-1051, a WEE1 inhibitor in Phase 1 for solid tumors, which recently achieved a confirmed partial response in the ACESOT-1051 trial.
Arch Biopartners: C$600,000 Non-Brokered Private Placement (March 30)
Arch Biopartners (TSX-V: ACH) announced a small C$600,000 non-brokered private placement (1 million shares at C$0.60) for general working capital. The company is developing LSALT peptide (Metablok) for organ injury.
Ongoing Tender Offers and Corporate Actions
Esperion / Corstasis Therapeutics acquisition closed April 2, 2026. Esperion completed its acquisition of Corstasis for $75 million upfront plus up to $180 million in regulatory and commercial milestones and low double-digit royalties (~10–15% estimated) on worldwide Enbumyst sales and follow-on products.
Advisors: Jefferies LLC (Esperion financial), PJT Partners (Corstasis financial), Gibson, Dunn & Crutcher LLP (Esperion legal), Arnold & Porter Kaye Scholer LLP (Corstasis legal).
The acquisition was funded by the concurrent $50 million Athyrium Japan royalty financing and $25 million incremental term loan described in the Athyrium/Esperion section above.
Clarification: The March 3 announcement referenced financing via "Athyrium Capital Management and HealthCare Royalty." The April 2 SEC 8-K resolves this definitively — the $50 million royalty purchase was executed solely by Athyrium Opportunities IV Acquisition LP. HealthCare Royalty's role is confined to co-lending in the $150 million senior secured credit facility (December 2024) and the $25 million incremental term loan.
Upstream IP on Enbumyst is clean: bumetanide is a decades-old generic molecule (off patent since the 1980s), and Corstasis developed its proprietary nasal formulation internally using the commercially available Aptar Pharma Unidose device. No third-party royalty obligations on Enbumyst were identified.
Gilead/Arcellx tender offer remained active during the W14 window, with expiration set for one minute after 11:59 PM ET on April 2, 2026. The $7.8 billion deal offers $115.00/share in cash plus a non-transferable CVR paying $5.00/share if cumulative anito-cel sales exceed $6 billion by December 31, 2029. No updated tender acceptance rates were reported during the window.
Takeda disclosed plans to lay off more than 600 U.S. employees as part of ongoing restructuring, announced March 30. Separately, Julie Kim officially joined Takeda's executive leadership team on April 1 as part of the extended CEO handover from Christophe Weber; Kim becomes President and CEO in June 2026.
FibroBiologics (NASDAQ: FBLG) executed a 1-for-20 reverse stock split effective March 30 to regain Nasdaq minimum bid price compliance. Outstanding shares were reduced from approximately 70.3 million to approximately 3.5 million.
Plus Therapeutics (NASDAQ: PSTV), a clinical-stage radiotherapeutics company focused on CNS cancers, executed a 1-for-25 reverse stock split effective April 2 for the same purpose. Outstanding shares were reduced from approximately 171.5 million to approximately 6.9 million.
BioAtla (NASDAQ: BCAB) approved a 1-for-50 reverse stock split effective April 6, 2026 to meet Nasdaq minimum bid price requirements. The company had previously reduced its workforce by approximately 70% in March 2026 and remains under Nasdaq delisting review.
Artelo Biosciences (NASDAQ: ARTL) announced an $11.0 million private placement of shares and warrants on March 30. No placement agent was disclosed.
NewcelX (OTCQB: NCXL) priced a $1.35 million equity financing on April 1, issuing approximately 490,907 shares at $2.75/share plus warrants for 687,270 shares at $3.025 exercise price.
Hoth Therapeutics (NASDAQ: HOTH) announced a $2.0 million registered direct offering on April 1, issuing 2,857,144 shares at $0.70 per share with concurrent unregistered warrants at $0.85 exercise, through sole placement agent H.C. Wainwright & Co. Closing was expected approximately April 2.
Bayer appointed Nelson Ambrogio as President of U.S. Pharmaceuticals effective May 1, 2026 (announced March 31), elevating its former head of diagnostic imaging to lead the company's largest single market as it seeks to restore pharmaceutical revenue growth following the Eylea biosimilar pressure and generic Xarelto entry.
Evotec named Dr. Ashiq Khan as Chief Commercial Officer effective April 1, as part of the company's ongoing "Horizon" transformation plan. Khan brings AI-enabled drug discovery commercialization experience and is tasked with rebuilding Evotec's commercial team following the leadership changes associated with the 2025 restructuring.
Damora Therapeutics appointed Jennifer Jarrett as President and CEO effective March 30, alongside board additions of Cameron Turtle (CEO of Spyre Therapeutics) and Mike Landsittel (former CFO of Blueprint Medicines). Damora is developing mutCALR-targeted therapies for myeloproliferative neoplasms (MPNs).
Distress and Restructuring
IO Biotech: Chapter 7 Liquidation Filed (March 31)
IO Biotech (NASDAQ: IOBT) filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware on March 31, ceasing all operations immediately. All employees were terminated and all board members resigned upon filing. The company reported assets of $1–$10 million against liabilities of $10–$50 million, including a €22.5 million European Investment Bank drawdown now in default.
IO Biotech's collapse followed sequentially from a failed Phase 3 pivotal study of its IO102-IO103 cancer vaccine in melanoma and a subsequent FDA recommendation against seeking approval on the existing data package. The company had raised approximately $158 million since its 2021 Nasdaq IPO but was unable to identify a buyer or restructuring partner following the Phase 3 failure. IO Biotech represents the largest Chapter 7 biotech liquidation of 2026 to date by IPO capitalization.
Iterim Therapeutics: Irish Liquidation and Nasdaq Suspension (March 27 / April 1)
Iterum Therapeutics (NASDAQ: ITRM) filed a winding-up petition in the Irish High Court on March 27, with joint provisional liquidators appointed. Nasdaq suspended trading of ITRM shares on April 1, with a Form 25-NSE filed to complete delisting. A court hearing on the winding-up order is set for April 13.
Iterum's only approved product, Orlynvah (sulopenem eropenem/probenecid), a novel oral carbapenem antibiotic for uncomplicated urinary tract infections (uUTI), failed to achieve commercial traction following its 2023 approval. Despite addressing an area of significant antimicrobial resistance concern, Orlynvah's modest prescriber uptake and narrow payer formulary access left the company unable to fund ongoing operations. The failure underscores the persistent commercialization challenge for novel antibiotics: regulatory approval does not translate to reimbursement or prescriber adoption without sustained investment in market access infrastructure that pre-revenue biotechs cannot typically sustain.
Lipella Pharmaceuticals: Chapter 11 Filing with 363 Sale Intent (March 30)
Lipella Pharmaceuticals (OTC: LIPO), a clinical-stage biotech based in Pittsburgh, filed a voluntary Chapter 11 petition in the U.S. Bankruptcy Court for the Western District of Pennsylvania on March 30. The company stated its intent to undergo a Section 363 sale process to maximize value for creditors. Lipella's pipeline includes LP-310 (intravesical tacrolimus for hemorrhagic cystitis) and LP-184 (a DNA-alkylating agent for rare cancers). No restructuring counsel or financial advisor was disclosed in the announcement.
Novo Nordisk: ~400 Layoffs at Bloomington, Indiana Facility (April 1)
Novo Nordisk announced approximately 400 layoffs at its Bloomington, Indiana manufacturing facility — roughly 22% of the site's workforce, leaving approximately 1,400 employees. The cuts are effective early May. The Bloomington site was acquired from Catalent as part of Novo Holdings' approximately $11 billion acquisition of Catalent in 2025, which was intended to secure dedicated GLP-1 manufacturing capacity for Novo's Ozempic and Wegovy franchises.
The site has faced FDA manufacturing quality issues, including a Warning Letter, since the acquisition. These layoffs are separate from Novo Nordisk's broader global restructuring program announced in September 2025 (targeting approximately 9,000 positions), which was driven by competitive pressure from Lilly's Zepbound (tirzepatide) and the anticipated market entry of oral GLP-1 products — a pressure now materially realized with Foundayo's April 1 approval. The Bloomington cuts may reflect a recalibration of manufacturing scale assumptions in light of the evolving competitive landscape.
bioMérieux: San Jose Site Closure Layoffs Begin (April 3)
bioMérieux initiated the first phase of 121 layoffs at its San Jose, California facility on April 3, per a California WARN Act notice filed with the state Employment Development Department. The entire Baytech Drive site will permanently close by end of 2026, with a second phase of layoffs scheduled for December. The closure reflects ongoing consolidation of bioMérieux's U.S. diagnostics manufacturing footprint.
Disclaimer: The author is not a lawyer or financial adviser. Nothing in this article constitutes investment, legal, or financial advice. All information is provided for informational purposes only. Deal terms and figures are based on publicly available sources and may be subject to revision.
Member discussion